var title_f32_45_33488="Ciclesonide: Drug information";
var content_f32_45_33488=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ciclesonide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/25/35220?source=see_link\">",
"       Ciclesonide (nasal): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/5/34902?source=see_link\">",
"       Ciclesonide (oral inhalation): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8537 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-189A616C48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_45_33488=[""].join("\n");
var outline_f32_45_33488=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/25/35220?source=related_link\">",
"      Ciclesonide (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/5/34902?source=related_link\">",
"      Ciclesonide (oral inhalation): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_45_33489="Prurigo nodularis histo";
var content_f32_45_33489=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Histologic features of prurigo nodularis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 146px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    On histopathologic examination, prurigo nodularis shows irregular epidermal hyperplasia, marked hyperkeratosis and parakeratosis, and dermal fibrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jennifer McNiff, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_45_33489=[""].join("\n");
var outline_f32_45_33489=null;
var title_f32_45_33490="Color flow Doppler moderate AR";
var content_f32_45_33490=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Color flow Doppler of aortic regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The color flow Doppler from the long axis precordial view shows moderate aortic regurgitation (AR) with a jet width at its origin (vena contracta) about half of the left ventricular outflow tract (LVOT) diameter (arrow). Panel A is an M-mode echocardiogram with color flow Doppler, obtained from the two dimensional echocardiogram in the plane indicated by the dotted line (M-line); the AR jet is seen within the left ventricle (LV).",
"    <div class=\"footnotes\">",
"     Ao: aorta.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_45_33490=[""].join("\n");
var outline_f32_45_33490=null;
var title_f32_45_33491="Carbetocin: Drug information";
var content_f32_45_33491=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carbetocin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/60/14275?source=see_link\">",
"    see \"Carbetocin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F239715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Duratocin&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9611014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Oxytocic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9611144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Prevention of uterine atony and postpartum bleeding:",
"     </b>",
"     I.V.: 100 mcg (single dose only)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F9612472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Duratocin&trade;: 100 mcg/mL (1 mL)",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11217373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9611145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer as bolus I.V. injection over 1 minute only after delivery of infant has been completed by cesarean section. May administer before or after delivery of placenta.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F239713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of uterine atony and postpartum hemorrhage following elective cesarean section under anesthesia (epidural or spinal)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9611010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes oxytocin (carbetocin analog) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9611071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &ge;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Flushing, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Feeling of warmth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 5%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Chest pain, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Anxiety, chills, dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Metallic taste",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9611020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to carbetocin, oxytocin, or any component of the formulation; administration prior to delivery of infant for any reason (including elective or medical induction of labor); vascular disease; use in children",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9611021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: Persistent bleeding warrants further evaluation to rule out coagulopathy,      genital tract trauma, or the presence of retained placental fragments.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endocrine disease: Excluding gestational diabetes, use in this population has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic disease: Use has not been studied in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal disease: Use has not been studied in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use has not been studied in patients with significant heart disease, hypertension, or history of coagulopathy. Use in patients with vascular disease (especially coronary artery disease) should be avoided. Employ extreme caution with use in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use in elderly women is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Carbetocin induced contractions are of a longer duration than those observed with oxytocin and are not stopped by discontinuation of therapy. Improper use during pregnancy may produce symptoms similar to those observed with oxytocin overdosage (eg, hyperstimulation of uterus, uterine rupture). Therapy should not be repeated if response to initial dose is inadequate; aggressive therapy with alternative agents (eg, oxytocin, ergonovine) should be utilized.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9611075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dinoprostone: May enhance the therapeutic effect of Carbetocin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Misoprostol: May enhance the therapeutic effect of Carbetocin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9611016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use in pregnancy prior to delivery is contraindicated. Carbetocin induced contractions are of a longer duration than those observed with oxytocin and are not stopped by discontinuation of therapy. Improper use during pregnancy may produce symptoms similar to those observed with oxytocin overdosage (eg, hyperstimulation of uterus, uterine rupture).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9611018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9611019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of carbetocin were detected in the breast milk of 5 healthy nursing women approximately 7-14 weeks postpartum though peak levels observed were 50 times lower than in plasma. Exposure to the breast-feeding infant is expected to be minimal and not expected to pose significant health risks as carbetocin in breast milk is rapidly degraded in the GI tract of a nursing infant. Ability of carbetocin to stimulate breast milk ejection (milk letdown) has not been determined.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9611147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Persistent postpartum bleeding; blood pressure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Duratocin (AR, AU, CL, CN, CZ, EC, HK, IT, KP, MY, NZ, PE, PH, SG, TH, UY);",
"     </li>",
"     <li>",
"      Pabal (AT, BE, CH, DE, DK, EE, FI, FR, GB, GR, HN, IE, NL, NO, PL, PT, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9612470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds oxytocin receptors located in uterine smooth muscle producing rhythmic uterine contractions characteristic to deliver, as well as increasing both the frequency of existing contractions and uterine tone. Enhances uterine involution early in postpartum.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9611125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: ~2 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: ~60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~29-53 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (&lt;1%, as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Borruto F, Treisser A, and Comparetto C, &ldquo;Utilization of Carbetocin for Prevention of Postpartum Hemorrhage After Cesarean Section: A Randomized Clinical Trial,&rdquo;",
"      <i>",
"       Arch Gynecol Obstet",
"      </i>",
"      , 2009, 280(5):707-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/45/33491/abstract-text/19229549/pubmed\" id=\"19229549\" target=\"_blank\">",
"        19229549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dansereau J, Joshi AK, Helewa ME, et al, &ldquo;Double-Blind Comparison of Carbetocin Versus Oxytocin in Prevention of Uterine Atony After Cesarean Section,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 1999, 180(3 Pt 1):670-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/45/33491/abstract-text/10076146/pubmed\" id=\"10076146\" target=\"_blank\">",
"        10076146",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silcox J, Schulz P, Horbay GL, et al, &ldquo;Transfer of Carbetocin Into Human Breast Milk,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 1993, 82(3):456-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/45/33491/abstract-text/8355953/pubmed\" id=\"8355953\" target=\"_blank\">",
"        8355953",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8562 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-FC54B750F8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_45_33491=[""].join("\n");
var outline_f32_45_33491=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F239715\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611014\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611144\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682481\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682482\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9612472\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11217373\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611145\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F239713\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611010\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611071\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611020\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611021\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298968\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611075\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611016\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611018\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611019\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611147\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961906\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9612470\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611125\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8562\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8562|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/60/14275?source=related_link\">",
"      Carbetocin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_45_33492="Griseofulvin: Pediatric drug information";
var content_f32_45_33492=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Griseofulvin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?5/61/6102?source=see_link\">",
"    see \"Griseofulvin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/56/38789?source=see_link\">",
"    see \"Griseofulvin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Grifulvin V&reg;;",
"     </li>",
"     <li>",
"      Gris-PEG&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Systemic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/61/6102?source=see_link\">",
"      see \"Griseofulvin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;2 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Microsize: 10-20 mg/kg/day in single or 2 divided doses.",
"     <b>",
"      Note:",
"     </b>",
"     Some references recommend high-dose griseofulvin (20-25 mg/kg/day) for 6-8 weeks for the treatment of tinea capitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ultramicrosize: 5-15 mg/kg/day once daily or in 2 divided doses; maximum dose: 750 mg/day in 2 divided doses for fungal infections like tinea pedis or tinea unguium which are more difficult to eradicate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Microsize: 500-1000 mg/day in single or divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ultramicrosize: 330-375 mg/day in single or divided doses; doses up to 750 mg/day have been used for infections more difficult to eradicate such as tinea pedis and tinea unguium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration of therapy depends on the site of infection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinea corporis: 2-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinea capitis: 4-6 weeks or longer (AAP",
"     <i>",
"      Red Book&reg;",
"     </i>",
"     recommends continuing treatment for 2 weeks after clinical resolution of symptoms)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinea pedis: 4-8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tinea unguium: 4-6 months or longer",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F177502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral [microsize]: 125 mg/5 mL (118 mL, 120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [microsize]: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Grifulvin V&reg;: 500 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [ultramicrosize]: 125 mg, 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gris-PEG&reg;: 125 mg, 250 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F177487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with a fatty meal (peanut butter or ice cream to increase absorption), or with food or milk to avoid GI upset; shake suspension well before use. Ultramicrosize tablets may be swallowed whole or crushed and sprinkled onto 1 tablespoonful of applesauce and taken immediately without chewing.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F4608120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of tinea infections of the skin and hair caused by susceptible species of",
"     <i>",
"      Microsporum",
"     </i>",
"     ,",
"     <i>",
"      Epidermophyton",
"     </i>",
"     , or",
"     <i>",
"      Trichophyton",
"     </i>",
"     .",
"     <b>",
"      Note:",
"     </b>",
"     Griseofulvin is no longer recommended for the treatment of onychomycosis.",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F177563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, headache, insomnia, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioneurotic edema (rare),  erythema multiforme-like drug reaction, photosensitivity, rash (most common), urticaria (most common),",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, epigastric distress, GI bleeding, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Granulocytopenia, leukopenia (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Nephrosis, proteinuria (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Drug-induced lupus-like syndrome (rare), oral thrush",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Bilirubin increased, liver transaminases increased, Stevens-Johnson syndrome, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to griseofulvin or any component; severe liver disease, porphyria (interferes with porphyrin metabolism); pregnant women (may cause fetal harm)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1047627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid exposure to intense sunlight to prevent photosensitivity reactions; use with caution in patients with penicillin hypersensitivity since cross-reactivity with griseofulvin is possible",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4608119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lupus erythematosus or lupus-like syndromes have been reported in patients receiving griseofulvin.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F177554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Induces",
"     </b>",
"     CYP1A2 (weak/moderate), CYP2C9 (weak/moderate), CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F177496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): Griseofulvin may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Weakly to Moderately Effective) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Griseofulvin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Methohexital; Thiopental.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Griseofulvin may increase the metabolism of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use an alternative, nonhormonal form of contraception, or use an alternative to griseofulvin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Griseofulvin may diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Griseofulvin may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Griseofulvin may decrease the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1047643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fatty meal will increase griseofulvin absorption",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4293494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal reproduction studies. Griseofulvin crosses the placenta. Because adverse events have also been observed in humans (two cases of conjoined twins), use during pregnancy is contraindicated. Effective contraception should be used during therapy and for 1 month after therapy is discontinued in women of reproductive potential.  Men should avoid fathering a child for at least 6 months after therapy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1047634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic renal, hepatic, and hematopoietic function tests",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1047626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits fungal cell mitosis at metaphase by disrupting the cell's mitotic spindle structure; binds to human keratin making it resistant to fungal invasion",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1047640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Ultramicrosize griseofulvin absorption is almost complete; absorption of microsize griseofulvin is variable (25% to 70% of an oral dose); absorbed from the duodenum",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Deposited in the keratin layer of skin, hair, and nails; concentrates in liver, fat, and skeletal muscles; crosses the placenta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive in the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 9-22 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &lt;1% excreted unchanged in urine; also excreted in feces and perspiration",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1047633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/56/38789?source=see_link\">",
"      see \"Griseofulvin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; notify physician if skin rash occurs",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ali S, Graham TA, and Forgie SE, \"The Assessment and Management of Tinea Capitis in Children,\"",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 2007,  23(9):662-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/45/33492/abstract-text/17876261/pubmed\" id=\"17876261\" target=\"_blank\">",
"        17876261",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleece D, Gaughan JP, and Aronoff SC, \"Griseofulvin Versus Terbinafine in the Treatment of Tinea Capitis: A Meta-Analysis of Randomized, Clinical Trials,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(5):1312-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/45/33492/abstract-text/15520113/pubmed\" id=\"15520113\" target=\"_blank\">",
"        15520113",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ginsburg CM, McCracken GH Jr, Petruska M, et al, &ldquo;Effect of Feeding on Bioavailability of Griseofulvin in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1983, 102(2):309-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/45/33492/abstract-text/6822943/pubmed\" id=\"6822943\" target=\"_blank\">",
"        6822943",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta AK, Adam P, Dlova N, et al, \"Therapeutic Options for the Treatment of Tinea Capitis Caused by",
"      <i>",
"       Trichophyton",
"      </i>",
"      Species: Griseofulvin Versus the New Oral Antifungal Agents, Terbinafine, Itraconazole, and Fluconazole,\"",
"      <i>",
"       Pediatr Dermatol",
"      </i>",
"      , 2001,  18(5):433-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/45/33492/abstract-text/11737692/pubmed\" id=\"11737692\" target=\"_blank\">",
"        11737692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta AK, Ryder JE, Nicol K, et al, \"Superficial Fungal Infections: An Update on Pityriasis Versicolor, Seborrheic Dermatitis, Tinea Capitis, and Onychomycosis,\"",
"      <i>",
"       Clin Dermatol",
"      </i>",
"      , 2003, 21(5):417-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/45/33492/abstract-text/14678722/pubmed\" id=\"14678722\" target=\"_blank\">",
"        14678722",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Higgins EM, Fuller LC, and Smith CH, \"Guidelines for the Management of Tinea Capitis. British Association of Dermatologists,\"",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 2000,  143(1):53-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/45/33492/abstract-text/10886135/pubmed\" id=\"10886135\" target=\"_blank\">",
"        10886135",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipozencic J, Skerlev M, Orofino-Costa R, et al, \"A Randomized, Double-Blind, Parallel-Group, Duration-Finding Study of Oral Terbinafine and Open-Label, High-Dose Griseofulvin in Children With Tinea Capitis Due to",
"      <i>",
"       Microsporum",
"      </i>",
"      Species,\"",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 2002, 146(5):816-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/45/33492/abstract-text/12000378/pubmed\" id=\"12000378\" target=\"_blank\">",
"        12000378",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2006 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 27th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2006, 654-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sethi A and Antaya R, \"Systemic Antifungal Therapy for Cutaneous Infections in Children,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2006, 25(7):643-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/45/33492/abstract-text/16804437/pubmed\" id=\"16804437\" target=\"_blank\">",
"        16804437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13342 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-3DA446CC7F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_45_33492=[""].join("\n");
var outline_f32_45_33492=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177520\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047635\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047628\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177502\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177487\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047638\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4608120\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047637\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177563\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047641\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047627\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4608119\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177554\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177496\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047643\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4293494\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047634\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047626\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047640\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047633\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13342\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13342|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/61/6102?source=related_link\">",
"      Griseofulvin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/56/38789?source=related_link\">",
"      Griseofulvin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_45_33493="Mirtazapine: Patient drug information";
var content_f32_45_33493=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Mirtazapine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     see \"Mirtazapine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F197109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Remeron SolTab&reg;;",
"     </li>",
"     <li>",
"      Remeron&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F197110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Mirtazapine&reg;;",
"     </li>",
"     <li>",
"      Auro-Mirtazapine;",
"     </li>",
"     <li>",
"      Ava-Mirtazapine;",
"     </li>",
"     <li>",
"      CO Mirtazapine;",
"     </li>",
"     <li>",
"      Dom-Mirtazapine;",
"     </li>",
"     <li>",
"      GD-Mirtazapine;",
"     </li>",
"     <li>",
"      Jamp-Mirtazapine;",
"     </li>",
"     <li>",
"      Mylan-Mirtazapine;",
"     </li>",
"     <li>",
"      Novo-Mirtazapine;",
"     </li>",
"     <li>",
"      PMS-Mirtazapine;",
"     </li>",
"     <li>",
"      PRO-Mirtazapine;",
"     </li>",
"     <li>",
"      ratio-Mirtazapine;",
"     </li>",
"     <li>",
"      Remeron&reg;;",
"     </li>",
"     <li>",
"      Remeron&reg; RD;",
"     </li>",
"     <li>",
"      Riva-Mirtazapine;",
"     </li>",
"     <li>",
"      Sandoz-Mirtazapine;",
"     </li>",
"     <li>",
"      Sandoz-Mirtazapine FC;",
"     </li>",
"     <li>",
"      ZYM-Mirtazapine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teens who take this drug may be at a greater risk of having thoughts or actions of suicide. Adults may also be at risk. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692021",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat post-traumatic stress.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702535",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to mirtazapine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4232023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking any of these drugs: Linezolid or methylene blue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with certain other drugs. Call your doctor right away if you have dizziness, very bad headache, agitation, hallucinations, fever, fast heartbeat, a heartbeat that does not feel normal, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly and with logic, very bad upset stomach and throwing up, or very bad loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Agitation, twitching, sweating, or muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695854",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime if it causes sleepiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral-disintegrating tablet:",
"        </span>",
"       </b>",
"       After opening, place on your tongue and let melt. Do not take with water. Do not crush, break, or chew.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699292",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect oral-disintegrating tablet from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10872 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-89.218.100.194-DA315AB02B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_45_33493=[""].join("\n");
var outline_f32_45_33493=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197109\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197110\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020344\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020346\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020345\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020350\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020351\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020353\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020348\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020349\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020354\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020355\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=related_link\">",
"      Mirtazapine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_45_33494="Treatment and prevention of mitochondrial toxicity in HIV-infected patients";
var content_f32_45_33494=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of mitochondrial toxicity in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/45/33494/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/45/33494/contributors\">",
"     Kees Brinkman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/45/33494/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/45/33494/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/45/33494/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/45/33494/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/45/33494/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the introduction of potent antiretroviral therapy, morbidity and mortality related to HIV infection has improved dramatically. However, chronic administration of antiretroviral medications can lead to various adverse events, including mitochondrial toxicity.",
"   </p>",
"   <p>",
"    This topic will address the management of mitochondrial toxicity by organ system. The pathogenesis, clinical manifestations, and diagnosis of mitochondrial toxicity is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=see_link\">",
"     \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of mitochondrial toxicity will depend on the target organ that is involved. Careful consideration of HIV resistance profiles also need to be made when switching from one nucleoside analog to another.",
"   </p>",
"   <p>",
"    If the clinician determines that there is no suitable alternative, switching to a nucleoside-sparing regimen (eg, a boosted double protease inhibitor combination with either a non-nucleoside analog",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    integrase inhibitor) may be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients who develop myopathy while taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    should be switched to an alternate nucleoside analogue, since this clinical manifestation is related only to this agent. In addition to drug discontinuation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    supplementation may also be considered, although there are no treatment trials supporting this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Lipoatrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases of lipoatrophy, a gradual increase of subcutaneous fat was observed in several studies when d4T was switched to either ZDV,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33494/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In subsequent studies, a switch from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    to abacavir or tenofovir showed modest improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33494/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Addition of uridine to d4T or AZT containing treatment in patients with lipoatrophy did not improve the content of limb fat [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33494/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some have proposed using a nucleoside analog-sparing regimen to reverse lipoatrophy. In a small study of 67 patients who were taking two nucleoside analogs plus",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"     ,",
"    </span>",
"    half were switched to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    plus",
"    <span class=\"nowrap\">",
"     lopinavir/ritonavir",
"    </span>",
"    combination with follow-up dual-energy X-ray absorptiometry (DEXA) scans; a subset of patients from each group were also evaluated for changes in the mitochondrial DNA to nuclear DNA ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33494/abstract/6\">",
"     6",
"    </a>",
"    ]. Although patients who switched regimens had improvement in their mitochondrial parameters, there was no significant difference between groups in DEXA scans at week 48 of follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Peripheral neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop peripheral neuropathy while taking ddI",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    d4T may have symptomatic improvement with replacement of these particular nucleoside analogues with other agents of the same class that have less toxicity (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    ). A trial of coenzyme Q to restore oxidative capacity in HIV-infected patients on ART led to an increase in neuropathic pain in patients with peripheral neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33494/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Asymptomatic hyperlactatemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with asymptomatic hyperlactatemia, substitution of the implicated nucleoside analogue with an alternative drug in the same class that has less mitochondrial toxicity is recommended. In patients with asymptomatic hyperlactatemia, lactate levels slowly normalized after d4T (&plusmn; ddI) were switched to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33494/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If avoidance of all nucleoside analogues is desired, an alternate regimen including two protease inhibitors, a nonnucleoside reverse transcriptase inhibitor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an integrase inhibitor can be considered. If options are limited due to documented HIV resistance, then ART may be discontinued temporarily while the patient is treated with medications, which may have a benefit on mitochondrial function (eg, riboflavin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    , thiamine, coenzyme Q). After one month of supplementation, the same ART regimen may be restarted with close monitoring. However, this option is less desirable since there are little clinical data supporting this approach.",
"   </p>",
"   <p>",
"    Routine monitoring of lactate levels is not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=see_link\">",
"     \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Symptomatic hyperlactatemia and lactic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In symptomatic hyperlactatemia or lactic acidosis (&plusmn; pancreatitis), one cannot risk progression to fatal outcomes by only switching the medication. In these situations, all HIV medications should be stopped immediately [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33494/abstract/9\">",
"     9",
"    </a>",
"    ] and the patient should be closely monitored in a hospitalized setting for potential clinical progression, despite ART discontinuation.",
"   </p>",
"   <p>",
"    Drug-induced lactic acidosis occurs in the absence of systemic hypoperfusion and is called type B lactic acidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3781?source=see_link&amp;anchor=H5#H5\">",
"     \"Causes of lactic acidosis\", section on 'Type B lactic acidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Resolution of lactic acidosis after drug discontinuation can be extremely slow; reported experience is from 4 to 28 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33494/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Furthermore, the lactate level itself may be a risk factor for mortality. The following observations were reported in a review of 12 cases of lactic acidosis in Spain and an additional 60 cases from the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33494/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the 12 index patients, symptoms were present for 1 to 12 weeks prior to diagnosis.",
"     </li>",
"     <li>",
"      Mortality rates overall were high (33 percent for the case series; 57 percent for those described in the literature review).",
"     </li>",
"     <li>",
"      In a multivariate analysis, a serum lactate level of &gt;10 mM was associated with higher mortality (odds ratio 13; 95% CI 2.96-59.25).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anecdotal case reports suggest that resumption of an altered ART regimen is safe after resolution of signs and symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33494/abstract/13\">",
"     13",
"    </a>",
"    ]. Nucleoside analogues that have little or no mitochondrial toxicity should be utilized (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    ). Alternatively, nucleoside analogues can be omitted altogether, and alternative regimens, utilizing boosted protease inhibitors, a non-nucleoside reverse transcriptase inhibitor,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an integrase inhibitor, can be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33494/abstract/12,14\">",
"     12,14",
"    </a>",
"    ]. In resource limited countries where the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    is common, therapeutic options are more limited when symptomatic hyperlactatemia ensues [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33494/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there are no controlled trials to prove their benefit, medications that support mitochondrial function should be given to patients with lactic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33494/abstract/12\">",
"     12",
"    </a>",
"    ]. Anecdotal success has been described for combinations of riboflavin (50 mg daily)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    (1000 mg twice daily), thiamine (100 mg daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33494/abstract/16-23\">",
"     16-23",
"    </a>",
"    ]. They are easily available (also intravenously) and are relatively harmless. Survival has also been described with the use of uridine (1000 mg three times daily), although this is not easily available and cannot be given intravenously [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33494/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dideoxynucleoside analogues are most closely associated with pancreatitis (ddI&gt;d4T), although it has not been clearly established whether the mechanism for this adverse event is related to mitochondrial toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=see_link\">",
"     \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of pancreatitis related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    is increased if used concomitantly with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for hepatitis C treatment; this combination is not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11848?source=see_link\">",
"     \"Evaluation of the HIV-infected patient with chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All medications with a potential association should be discontinued in any patient presenting with pancreatitis, including drugs other than nucleoside analogs. A comprehensive discussion on the etiologies of acute pancreatitis is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=see_link\">",
"     \"Etiology of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of mitochondrial toxicity is clearly lower if antiretroviral regimens include drugs with low affinity for mitochondrial DNA polymerase gamma, which is exclusively responsible for the replication of mitochondrial DNA (mtDNA). Drugs with a favorable toxicity profile include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=see_link\">",
"     \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, in resource-poor countries, low-cost treatment options such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    are still in use. One small randomized pilot study performed in the United States evaluated whether reducing the dose of stavudine may reduce lipoatrophy and mitochondrial toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33494/abstract/25\">",
"     25",
"    </a>",
"    ]. Dose reduction did not lead to improvement in fat atrophy subjectively or objectively at 48 weeks, but did lead to improvement in fat mtDNA. Loss of viral suppression was comparable among both arms and associated with lack of adherence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      By inhibiting mitochondrial DNA (mtDNA) enzyme polymerase-gamma, NRTIs can lead to depletion of mtDNA, resulting in organelle dysfunction and impairment of oxidative phosphorylation. Early effects of mitochondrial toxicity include decreased energy production and increased production of lactate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=see_link&amp;anchor=H2#H2\">",
"       \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\", section on 'Role of mitochondria'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Implicated drugs",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In vitro, the order of strength of inhibiting polymerase gamma for the different NRTIs is: ddC&gt; ddI &gt; d4T &ge; ZDV &gt;&gt;&gt; TDF = 3TC = FTC = ABC. Clinical data also support the close association of ddI and d4T with mitochondrial toxicity. Zalcitabine (ddC) used to give severe neuropathy and was withdrawn from the market in 2005. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=see_link&amp;anchor=H6#H6\">",
"       \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\", section on 'Implicated drugs'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical presentation and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical manifestations include myopathy, neuropathy, lipoatrophy, and lactic acidosis.",
"     </li>",
"     <li>",
"      The gold standard for the diagnosis of nucleoside-related mitochondrial toxic effects is a muscle or liver biopsy to assess evidence of abnormal mitochondrial structure.",
"     </li>",
"     <li>",
"      Serum lactate should be assessed in any patient with symptoms of nausea, vomiting, abdominal pain or bloating, or rapid weight loss. Levels need to be assessed with the strictest of quality control measures since elevated lactate can be an artifact of collection techniques. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=see_link&amp;anchor=H18#H18\">",
"       \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prospective monitoring of serum lactate levels has a poor predictive value and is not recommended. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=see_link&amp;anchor=H19#H19\">",
"       \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\", section on 'Patient monitoring'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for mitochondrial toxicity will depend on the target organ involved. Careful consideration of HIV resistance profiles need to be evaluated whenever changing antiretroviral medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Myopathy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with myopathy who are taking ZDV, we recommend discontinuation of ZDV.",
"     </li>",
"     <li>",
"      We recommend substitution of ZDV with another nucleoside analogue, appropriate for the patient's HIV resistance profile (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Lipoatrophy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of lipoatrophy will strongly depend on patient preference. In patients who are troubled by the cosmetic appearance of lipoatrophy, we recommend discontinuation of d4T or ZDV.",
"     </li>",
"     <li>",
"      In the patient who chooses to stop d4T or ZDV, we recommend use of an alternate nucleoside analogue with less mitochondrial toxicity (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Asymptomatic hyperlactatemia",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are little clinical data to guide management in patients with asymptomatic hyperlactatemia. In patients who have confirmation of elevated lactate levels on two occasions, we recommend substitution of the implicated agent with an alternative nucleoside analogue with less mitochondrial toxicity (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=see_link&amp;anchor=H6#H6\">",
"       \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\", section on 'Implicated drugs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If avoidance of all nucleoside analogues is desired, then an alternative regimen could include two protease inhibitors, a nonnucleoside reverse transcriptase inhibitor,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an integrase inhibitor. If options are limited due to documented HIV resistance, then ART may be discontinued temporarily while the patient is treated with medications, which may have a benefit on mitochondrial function (eg, riboflavin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      , thiamine). After one month of supplementation, the same ART regimen may be restarted with monitoring of symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Symptomatic hyperlactatemia/lactic acidosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In symptomatic hyperlactatemia or lactic acidosis, we recommend that all HIV medications should be stopped immediately (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with lactic acidosis or rising levels of hyperlactatemia should be closely monitored in a hospitalized setting for potential progression despite ART discontinuation.",
"     </li>",
"     <li>",
"      After resolution of the signs and symptoms of lactic acidosis, we recommend using nucleoside analogues with a more favorable toxicity profile (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Alternatively, the patient may be treated with two protease inhibitors, a nonnucleoside reverse transcriptase inhibitor,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an integrase inhibitor.",
"     </li>",
"     <li>",
"      We do",
"      <strong>",
"       NOT",
"      </strong>",
"      recommend reinitiation of ddI or d4T in patients with a history of severe lactic acidosis, even if treatment options are limited, due to the risk of recurrent lactic acidosis (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). In such patients, consultation with an HIV specialist who is expert in salvage therapy or referral to a research treatment protocol with an investigational agent may be considered.",
"     </li>",
"     <li>",
"      In hospitalized patients with severe lactic acidosis, we suggest the use of medications that support mitochondrial function (eg, riboflavin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       L-carnitine",
"      </a>",
"      or thiamine)&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/1\">",
"      Moyle GJ, Baldwin C, Langroudi B, et al. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003; 33:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/2\">",
"      McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004; 38:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/3\">",
"      Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/4\">",
"      Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/5\">",
"      McComsey GA, O'Riordan M, Choi J, et al. Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir. Antivir Ther 2012; 17:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/6\">",
"      Negredo E, Mir&oacute; O, Rodr&iacute;guez-Santiago B, et al. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). Clin Infect Dis 2009; 49:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/7\">",
"      Rabing Christensen E, Stegger M, Jensen-Fangel S, et al. Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high-dose coenzyme Q treatment: a randomized, double-blind, placebo-controlled pilot study. Clin Infect Dis 2004; 39:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/8\">",
"      Garc&iacute;a-Benayas T, Blanco F, de la Cruz JJ, et al. Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy. AIDS 2003; 17:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/9\">",
"      Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/10\">",
"      Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14:F25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/11\">",
"      C&ocirc;t&eacute; HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/12\">",
"      Falc&oacute; V, Rodr&iacute;guez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 2002; 34:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/13\">",
"      Delgado J, Harris M, Tesiorowski A, Montaner JS. Symptomatic elevations of lactic acid and their response to treatment manipulation in human immunodeficiency virus-infected persons: a case series. Clin Infect Dis 2001; 33:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/14\">",
"      Khouri S, Cushing H. Lactic acidosis secondary to nucleoside analogue antiretroviral therapy. AIDS Read 2000; 10:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/15\">",
"      Songa PM, Castelnuovo B, Mugasha EB, et al. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda). Clin Infect Dis 2007; 45:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/16\">",
"      Arici C, Tebaldi A, Quinzan GP, et al. Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART. Int J STD AIDS 2001; 12:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/17\">",
"      Brinkman K, Vrouenraets S, Kauffmann R, et al. Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis. AIDS 2000; 14:2801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/18\">",
"      Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002; 31:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/19\">",
"      Venhoff N, Setzer B, Lebrecht D, Walker UA. Dietary supplements in the treatment of nucleoside reverse transcriptase inhibitor-related mitochondrial toxicity. AIDS 2002; 16:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/20\">",
"      Claessens YE, Cariou A, Chiche JD, et al. L-Carnitine as a treatment of life-threatening lactic acidosis induced by nucleoside analogues. AIDS 2000; 14:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/21\">",
"      Fouty B, Frerman F, Reves R. Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet 1998; 352:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/22\">",
"      Luzzati R, Del Bravo P, Di Perri G, et al. Riboflavine and severe lactic acidosis. Lancet 1999; 353:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/23\">",
"      Claessens YE, Cariou A, Monchi M, et al. Detecting life-threatening lactic acidosis related to nucleoside-analog treatment of human immunodeficiency virus-infected patients, and treatment with L-carnitine. Crit Care Med 2003; 31:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/24\">",
"      Walker UA, Langmann P, Miehle N, et al. Beneficial effects of oral uridine in mitochondrial toxicity. AIDS 2004; 18:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33494/abstract/25\">",
"      McComsey GA, Lo Re V 3rd, O'Riordan M, et al. Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clin Infect Dis 2008; 46:1290.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3776 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-9CA6F9C4F1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_45_33494=[""].join("\n");
var outline_f32_45_33494=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Lipoatrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Peripheral neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Asymptomatic hyperlactatemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Symptomatic hyperlactatemia and lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Implicated drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Myopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Lipoatrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Asymptomatic hyperlactatemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Symptomatic hyperlactatemia/lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/44/3781?source=related_link\">",
"      Causes of lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=related_link\">",
"      Etiology of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11848?source=related_link\">",
"      Evaluation of the HIV-infected patient with chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=related_link\">",
"      Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_45_33495="Sertoli Leydig cell tumor";
var content_f32_45_33495=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sertoli-Leydig cell tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross specimen of a Sertoli-Leydig cell tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with the permission from Berek, JS, Hacker, NF. Practical Gynecologic Oncology, 3rd ed. Lippincott Williams &amp; Wilkins, Philadelphia, 2000, p. 225.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_45_33495=[""].join("\n");
var outline_f32_45_33495=null;
var title_f32_45_33496="Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients";
var content_f32_45_33496=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/45/33496/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/45/33496/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/45/33496/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/45/33496/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/45/33496/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/45/33496/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/45/33496/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anemia of chronic kidney disease (CKD) is, in most patients, normocytic and normochromic. It is principally due to reduced renal erythropoietin production and, to a lesser degree, to shortened red cell survival and decreased responsiveness to the hormone.",
"   </p>",
"   <p>",
"    Anemia can develop well before the onset of uremic symptoms due to end-stage renal disease (ESRD). Although anemia due to renal dysfunction generally develops when the glomerular filtration rate (GFR) declines to less than 30",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    it can also be observed in those with markedly higher GFRs (such as 60",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    and tends to occur at higher levels of GFR in African Americans than whites.",
"   </p>",
"   <p>",
"    If left untreated, the anemia of CKD is associated with several abnormalities. These include deterioration in cardiac function, decreased cognition and mental acuity, fatigue, and other signs and symptoms. There are also associations with an increased risk of morbidity and mortality, principally due to cardiac disease and stroke.",
"   </p>",
"   <p>",
"    The primary therapeutic options for the anemia of CKD include red blood cell transfusions, erythropoietin stimulating agents (ESAs), and, to a much lesser degree, androgens.",
"   </p>",
"   <p>",
"    The use of erythropoietin in the treatment of anemia of CKD in predialysis patients with CKD is discussed in this topic review. A discussion of its use in hemodialysis and peritoneal dialysis patient is presented separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia is a common feature in many patients with chronic kidney disease (CKD) who do not require dialysis, with decreasing hemoglobin levels as glomerular filtration rates (GFRs) decline below 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. As an example, based upon over 15,000 participants in the NHANES survey, the prevalence of anemia (hemoglobin [Hb] &lt;12",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in men and &lt;11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in women) increased from one percent at an estimated GFR of 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 to 9 percent at an estimated GFR of 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 and to 33 to 67 percent at an estimated GFR of 15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, the anemia of CKD, if left untreated, can result in deterioration in cardiac function, and decreased cognition and mental acuity. It can also be accompanied by debilitating symptoms, such as fatigue, weakness, lethargy, anorexia, and sleep disturbances. In addition, anemic patients commonly lack the stamina needed to perform normal daily activities or to work.",
"   </p>",
"   <p>",
"    Furthermore, anemia in patients with CKD is also associated with an increased risk of morbidity and mortality principally due to cardiac disease and stroke, and with an increased risk of hospitalization, hospital length of stay, and mortality in patients with predialysis CKD. Associations, however, do not prove causality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary therapeutic options for the anemia of CKD include red blood cell transfusions, erythropoietin stimulating agents (ESAs), and, to a much lesser degree, androgens.",
"   </p>",
"   <p>",
"    The administration of ESAs is particularly attractive because they have substantially reduced the need for red cell transfusions (with an attendant decrease in",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    risk for transfusion-related complications). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the hemoglobin concentration at which to initiate ESAs is not known with certainty and the safety of ESAs in treating even severe anemia has not been evaluated in large placebo controlled trials. We agree with the 2012 KDIGO guidelines that the potential benefits of reducing blood transfusions and anemia-related symptoms should be balanced against the harm in individual patients (such as stroke, vascular access loss, and hypertension) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/4\">",
"     4",
"    </a>",
"    ]. The following sections discuss the use and specific indications for erythropoietin. The use of darbepoetin, a different erythropoietic agent, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23896?source=see_link\">",
"     \"Darbepoetin alfa for the management of anemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     USE IN PREDIALYSIS PATIENTS WITH CHRONIC KIDNEY DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Efficacy and benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;EPO effectively corrects the anemia in patients with CKD who do not yet require dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. Compared to patients with severe anemia, increased hemoglobin levels may provide several benefits, including reduction in need for transfusion, the amelioration of anemia-induced symptoms, and perhaps cardiovascular improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/7-12\">",
"     7-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Progression of renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia may be a risk factor for progression of chronic renal dysfunction to end-stage renal disease (ESRD). As an example, one four year study of over 1500 patients with diabetic nephropathy found that, compared to patients with the highest baseline hemoglobin levels (&gt;13.8",
"    <span class=\"nowrap\">",
"     g/dL),",
"    </span>",
"    patients with lower hemoglobin levels had a nearly twofold increase in the adjusted risk of developing end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/13\">",
"     13",
"    </a>",
"    ]. From animal models of ischemic and nephrotoxic renal injury, various mechanisms underlying the renoprotective effects of erythropoietin have been proposed. These include reduced apoptosis, increased tubular regeneration, and decreased caspase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is conflicting evidence concerning the effect of correction of anemia on the rate of progression of renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a European study, 88 patients with chronic kidney disease (serum creatinine concentrations between 2 to 6",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [178 to 530",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"      and anemia (Hb concentration of 9 to 11.6",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      were randomly assigned to early or deferred therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/17\">",
"       17",
"      </a>",
"      ]. Early therapy consisted of the immediate administration of EPO to attain Hb levels of greater than 13",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      while the other arm deferred therapy until Hb levels were less than 9",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      At a 23-month follow-up, the primary end point (composite of doubling of serum creatinine concentration, renal replacement, or death) was significantly more likely in the deferred treatment arm (23 versus 13 patients, respectively).",
"     </li>",
"     <li>",
"      Although discussed in detail separately, the CREATE study evaluated outcomes, including the rate of decline in the GFR, among predialysis patients randomly assigned to Hb concentrations between 11 and 12.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or between 13 and 15",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/19\">",
"       19",
"      </a>",
"      ]. During the three-year study, there was no significant difference in the rate of decrease in estimated GFR (3.6 and 3.1 mL per minute per year in the high and low Hb groups, respectively). Although more patients assigned to the high Hb group required dialysis, the significance of this difference is unclear given that there was no set criteria for initiation of dialysis. In addition, the CHOIR study, another trial that evaluated the effects of either low or high Hb target values, found no difference in the percentage of patients who required renal replacement therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/20\">",
"       20",
"      </a>",
"      ]. A review of the CREATE and CHOIR studies can be found elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=see_link\">",
"       \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A lack of response to erythropoiesis stimulating agents (ESAs) may be associated with more rapid progression to ESRD. This was suggested by a study of 194 consecutive CKD patients who started ESAs between 2002 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients were classified as poor, intermediate, and good responders based upon their response to the first administered ESA dose. Responsiveness was calculated according the formula:",
"    <span class=\"nowrap\">",
"     (Hb",
"     <sub>",
"      1",
"     </sub>",
"     -Hb",
"     <sub>",
"      0",
"     </sub>",
"     )/time/ESA",
"    </span>",
"    dose where Hb",
"    <sub>",
"     1",
"    </sub>",
"    and Hb",
"    <sub>",
"     0",
"    </sub>",
"    correspond to Hb values at the first visit after ESA administration and at baseline, respectively; time refers to the period between visits; and ESA dose is the first weekly dose prescribed. ESA responsiveness was expressed as",
"    <span class=\"nowrap\">",
"     g/dL/month,",
"    </span>",
"    standardized to 10",
"    <span class=\"nowrap\">",
"     mcg/week.",
"    </span>",
"    During a median follow-up of three years, poor responsiveness was associated with a higher risk of ESRD (hazard ratio 2.49, 95% CI 1.28-4.84). The mechanism underlying this possible association is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Iron issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;An adequate response to EPO requires the maintenance of sufficient iron stores, which usually requires the administration of either oral or intravenous iron in patients with initially inadequate iron levels. Thus, EPO should NOT be started until iron status has been evaluated, and iron supplements should be given first in patients with evidence of iron deficiency. In addition, other causes of anemia should be excluded and hypertension should be corrected before EPO therapy is begun. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=see_link\">",
"     \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Whom to treat and target hemoglobin level",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FDA recommendation, as noted in the prescribing information, indicates that patients with chronic renal failure not on dialysis should have a hemoglobin level less than 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    prior to starting treatment.",
"   </p>",
"   <p>",
"    We agree with the 2012 KDIGO guidelines that among CKD patients who are not on hemodialysis, the decision to initiate ESA therapy should be individualized based on the rate of fall of hemoglobin concentration, prior response to iron therapy, risk of needing a transfusion, risks related to ESA therapy and the presence of anemia-related symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/4\">",
"     4",
"    </a>",
"    ]. As discussed in detail separately, we target hemoglobin levels in the range of 10 to 11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    among EPO and darbepoetin-treated predialysis patients with CKD, using the lowest possible ESA dose. We would use ESAs particularly cautiously in patients with active or prior malignancies. In many patients, the risk of stroke and increased death related to malignancy may outweigh any potential benefits of EPO or darbepoetin in the absence of severe anemia. We generally recommend NOT targeting Hb levels above 13",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial EPO dose should be approximately 50 to 100",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per week. In patients with chronic kidney disease who are not on dialysis, EPO is commonly given only once per week (or less frequently). Because of patient convenience and the need to preserve veins for future hemodialysis access, we recommend that EPO be administered subcutaneously in this setting. As previously discussed, subcutaneous EPO is highly effective in non-hemodialysis patients. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Efficacy and benefits'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In practice, most patients are dosed by unit dosing (eg, a vial), rather than on a",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    basis. Thus, we suggest that therapy in most patients begin at 10,000 units subcutaneously once weekly or 20,000 units subcutaneously every other week. However, the use of lower doses would also be reasonable, particularly in patients with pretreatment Hb levels near 11",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    If necessary, subsequent adjustments are made in interval",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dose. As discussed below, higher doses given less frequently have also been used, although the long-term safety and benefit of this approach are not known.",
"   </p>",
"   <p>",
"    Monitoring of the hemoglobin level every two to four weeks is recommended, which is commonly used in practice; however, current recommendations from the FDA are for more frequent testing.",
"   </p>",
"   <p>",
"    A number of well-designed prospective studies have demonstrated the effectiveness and short-term safety of weekly or even less frequent dosing regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/22-27\">",
"     22-27",
"    </a>",
"    ]; the long-term safety of such regimens has not been demonstrated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once weekly dosing was studied in a prospective, nonrandomized, multicenter anemia-correction trial of over 1,500 predialysis patients with anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/22\">",
"       22",
"      </a>",
"      ]. They received subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"       epoetin alfa",
"      </a>",
"      for 16 weeks, starting at 10,000 units once per week, with the dose increased at five weeks to 20,000 units once weekly if the hemoglobin concentration had not increased more than 1",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      Almost 90 percent of patients responded to once weekly dosing (mean hemoglobin level increased from 9.1 to 11.6",
"      <span class=\"nowrap\">",
"       g/dL).",
"      </span>",
"     </li>",
"     <li>",
"      Other data also indicate that as many as 75 percent of patients can reach target hemoglobin levels with less frequent than weekly dosing of EPO [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. In the PROMPT maintenance-conversion study, 519 patients with CKD and epoetin-treated anemia (baseline hemoglobin &gt;11",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      were randomly assigned to receive 10,000, 20,000, 30,000 and 40,000 units of subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"       epoetin alfa",
"      </a>",
"      every one, two, three and four weeks, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/24\">",
"       24",
"      </a>",
"      ]. At the end of the 16-week treatment period, mean hemoglobin had decreased by approximately 1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      in the groups treated every three and four weeks, but mean hemoglobin was statistically non-inferior, and remained",
"      <span class=\"nowrap\">",
"       &gt;11g/dL",
"      </span>",
"      in all four groups.",
"     </li>",
"     <li>",
"      An open-label randomized study demonstrated that EPO 40,000 units every four weeks was not inferior to EPO 20,000 units every two weeks as initial therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/28\">",
"       28",
"      </a>",
"      ]. In addition, an increase of &ge;1",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      was observed among 90, 87, 75, and 86 percent of patients administered EPO at 10,000 units per week, 20,000 units every two weeks, 20,000 units every four weeks, and 40,000 units every four weeks, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As discussed in detail elsewhere, there is limited evidence suggesting that an increased mortality in predialysis patients may be due to high ESA doses. Thus, we suggest that the dose of epoetin alpha generally not exceed 20,000 units per week in CKD patients who are not on dialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adverse effects associated with erythropoietin in predialysis patients are similar to those observed in hemodialysis patients. An important issue that is shared is the increased risk of adverse cardiovascular effects with increased hemoglobin levels. However, hypertension due to EPO is less of an issue in predialysis patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link&amp;anchor=H15#H15\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\", section on 'Side effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=see_link&amp;anchor=H14#H14\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     USE IN PERITONEAL DIALYSIS PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are some differences in the management of anemia in peritoneal dialysis (PD) patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Compared with hemodialysis patients, for example, hemoglobin levels should be relatively better preserved in PD patients since ongoing blood losses are less, due to fewer blood draws and less blood loss with the technique itself. In addition, PD may result in a lower rate of general stimulation of the immune system, thereby resulting in less \"functional anemia.\"",
"   </p>",
"   <p>",
"    As with hemodialysis patients, there has been a trend towards increasing hemoglobin levels among peritoneal dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/31\">",
"     31",
"    </a>",
"    ]. Hemoglobin levels have been observed to be higher at dialysis initiation among peritoneal dialysis patients compared to hemodialysis patients, and tend to remain higher, at least during the first six months on dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For practically all treatment issues, the management of anemia of CKD using erythropoietin is similar in predialysis patients with CKD and peritoneal dialysis patients. The following is a review of some of the issues related to the use of EPO in peritoneal dialysis patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Iron issues and exclusion of non-renal anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An erythropoietic agent should not be started until iron status has been evaluated. Iron supplements should be given first in patients with evidence of iron deficiency. Other causes of anemia should also be excluded and hypertension corrected before EPO therapy is begun. A detailed discussion related to assessment of iron stores and initial and maintenance dosing for iron therapy can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=see_link\">",
"     \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Erythropoietin efficacy and dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial evaluation, indications, dosing, target hemoglobin levels, adverse effects, and monitoring issues with EPO are similar to those with chronic kidney disease not on dialysis, as previously discussed.",
"   </p>",
"   <p>",
"    As with other patients with CKD, subcutaneous EPO is highly effective in raising hemoglobin levels in peritoneal dialysis patients with anemia due to CKD. Studies that have addressed this issue are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5\">",
"     'Efficacy and benefits'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Compared with the intravenous route, which is often used for reasons of convenience in hemodialysis patients, subcutaneous administration of EPO is preferred for convenience for the treatment of anemia in patients undergoing maintenance peritoneal dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited evidence suggests that androgens may be effective among some older male peritoneal dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/33\">",
"     33",
"    </a>",
"    ]. However, androgens, which have been used to lower the dose requirements for EPO in hemodialysis patients, are associated with side effects that limit their use [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/8/9353?source=see_link\">",
"     \"Non-iron pharmacologic adjuvants to erythropoiesis stimulating agent therapy in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Peginesatide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peptides that mimic the action of erythropoietin may eliminate the need for recombinant EPO in renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=see_link\">",
"     Peginesatide",
"    </a>",
"    is a synthetic peptide that activates the EPO receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/37\">",
"     37",
"    </a>",
"    ]. Peginesatide stimulates erythroid colony growth, reticulocyte count and hematocrit in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/38\">",
"     38",
"    </a>",
"    ], but, because its amino acid sequence is unrelated to erythropoietin, does not cross react with erythropoietin antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The US Food and Drug Administration has approved",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=see_link\">",
"     peginesatide",
"    </a>",
"    for intravenous or subcutaneous administration to treat anemia in adult dialysis patients with CKD but not in CKD patients who are not on dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link&amp;anchor=H1130568215#H1130568215\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\", section on 'Peginesatide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=see_link\">",
"     peginesatide",
"    </a>",
"    among CKD patients who are not on dialysis is not known. In a phase 2 dose-finding study of 139 CKD patients who were not on dialysis and not receiving erythropoietin, peginesatide administered every four weeks increased hemoglobin in greater than 90 percent of patients, with comparable responses observed for intravenous and subcutaneous routes of administration. Adverse events possibly related to peginesatide occurred in 12 percent and included hypertension, arthritis, and headache (6.5, 1.4, and 1.4 percent, respectively). Follow-up was limited to 24 weeks.",
"   </p>",
"   <p>",
"    However subsequent phase 3 studies raised concerns about the safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=see_link\">",
"     peginesatide",
"    </a>",
"    . Two randomized, controlled open-label phase 3 trials (PEARL 1 and PEARL 2) compared the efficacy and safety of peginesatide (starting dose 0.025 mg or 0.04",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight) with that of darbepoetin (0.75",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    body weight) among 983 nondialysis CKD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/41\">",
"     41",
"    </a>",
"    ]. Dosages were titrated to achieve and maintain hemoglobin concentrations between 11.0 and 12.0",
"    <span class=\"nowrap\">",
"     g/dl",
"    </span>",
"    for 52 weeks or more.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=see_link\">",
"     Peginesatide",
"    </a>",
"    was noninferior to darbepoetin in increasing and maintaining target hemoglobin concentrations. However, compared with darbepoetin, peginesatide was associated with a higher incidence of a composite cardiovascular safety endpoint that included death, stroke, myocardial infarction, congestive heart failure, unstable angina, or arrhythmia (17.1 versus 21.5 percent respectively, hazard ratio of 1.32 [95% CI 0.97-1.81]). Furthermore, compared with darbepoetin, peginesatide was associated with a higher incidence of sudden death (0.3 versus 2.1 percent, respectively) and acute kidney injury (4.3 versus 8.5 percent, respectively). Although the peginesatide group was slightly older and characterized by higher prevalence of diabetes and baseline cardiovascular disease, adjustments for these variables did not fully account for the inferior safety profile of peginesatide. The reasons for the peginesatide-associated increase in cardiovascular endpoints are not known [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/31/26102?source=see_link\">",
"     Peginesatide",
"    </a>",
"    has been withdrawn from the market due to serious hypersensitivity reactions reported in approximately 0.2 percent of patients following the first dose of intravenous administration with death occurring in 0.02 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Continuous Erythropoiesis Receptor Activator",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous Erythropoiesis Receptor Activator (CERA; methoxy polyethylene glycol-epoetin beta) is a pegylated form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    . It is thought to have the ability to repeatedly activate the erythropoiesis receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/44\">",
"     44",
"    </a>",
"    ]. This, in combination with an extended serum half life, as has been seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"     darbepoetin alfa",
"    </a>",
"    , permits dosing intervals of up to once every four weeks to help maintain desired Hb levels. Several studies consisting of over 1200 dialysis patients found that CERA (given once or twice monthly) and erythropoietin (given one to three times weekly) were similarly effective in maintaining Hb levels [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. CERA was also well tolerated. Similar effects of CERA have been reported in naive CKD patients not yet on dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33496/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although available in some European countries and approved by the FDA of the United States, legal issues are likely to prevent this agent from becoming available in the United States for several years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anemia is a common feature in many patients with chronic kidney disease (CKD) who do not require dialysis, with decreasing hemoglobin levels as glomerular filtration rates (GFRs) decline below 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The anemia of CKD, if left untreated, can result in deterioration in cardiac function, decreased cognition and mental acuity, and a host of debilitating symptoms. There are also associations with an increased risk of morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview of treatment options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Red blood cell transfusions, androgens, and erythropoietic stimulating agents are the primary options available for the management of anemia associated with CKD. In the United States, the two principal erythropoietic stimulating agents are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"       recombinant human erythropoietin",
"      </a>",
"      (EPO) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"       darbepoetin alfa",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview of treatment options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Erythropoietin-stimulating agents are highly effective in treating the anemia of CKD. They have reduced the need for red cell transfusions and have helped mobilize iron stores. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Efficacy and benefits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision to initiate ESA therapy should be individualized. For most predialysis and peritoneal dialysis patients with CKD who have symptoms attributable to anemia, we initiate ESAs when the Hb level is &lt;10",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      However, we are attentive to possible symptoms of anemia in younger patients who have CKD with few co-morbidities whose symptoms of anemia occur at higher Hb levels; for such patients we may initiate ESAs at Hb levels of 10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      or even higher after discussing potential risks and benefits with each patient. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=see_link&amp;anchor=H2#H2\">",
"       \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\", section on 'Target levels'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Predialysis and peritoneal dialysis patients who are being considered for treatment with erythropoietin-stimulating agents should meet the following criteria:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An initial hemoglobin level of less than 10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      should be present.",
"     </li>",
"     <li>",
"      Iron status has been evaluated and iron deficiency corrected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=see_link\">",
"       \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other treatable causes of anemia (eg, hemolysis, nutritional deficiency [eg, B12, folate]) have been excluded or treated if present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link\">",
"       \"Approach to the adult patient with anemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient should not have a history of stroke or malignancy, or an active malignancy without careful consideration of the potential risks and benefits of ESA use in this setting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among predialysis patients and peritoneal dialysis who meet these criteria, we generally use an erythropoietic agent rather than red blood cell transfusions or androgens. Either EPO or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/49/33560?source=see_link\">",
"       darbepoetin alfa",
"      </a>",
"      can be used, with the choice determined by patient and staff convenience, compliance, availability, and cost. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview of treatment options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among predialysis and peritoneal dialysis patients, we administer EPO subcutaneously rather than intravenously. The initial dose of EPO is usually 10,000 units subcutaneously once weekly or 20,000 units subcutaneously every other week. However, the use of lower doses would also be reasonable, particularly in patients with pretreatment Hb levels near 10",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      If necessary, subsequent adjustments are made in interval",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dose. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For predialysis and peritoneal dialysis patients treated with EPO, we suggest that maintenance supplemental iron be given to maintain a transferrin saturation between 20 to 50 percent and a serum ferritin level between 100 and 500",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=see_link\">",
"       \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/1\">",
"      Hsu CY. Epidemiology of anemia associated with chronic renal insufficiency. Curr Opin Nephrol Hypertens 2002; 11:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/2\">",
"      Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002; 13:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/3\">",
"      Astor BC, Muntner P, Levin A, et al. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002; 162:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/4\">",
"      KDIGO clinical practice guidelines for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/5\">",
"      Lim VS, DeGowin RL, Zavala D, et al. Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 1989; 110:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/6\">",
"      Roth D, Smith RD, Schulman G, et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 1994; 24:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/7\">",
"      Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995; 25:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/8\">",
"      Portol&eacute;s J, Torralbo A, Martin P, et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997; 29:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/9\">",
"      Fink J, Blahut S, Reddy M, Light P. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001; 37:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/10\">",
"      Li S, Collins AJ. Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int 2004; 65:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/11\">",
"      Jones M, Ibels L, Schenkel B, Zagari M. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int 2004; 65:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/12\">",
"      Xue JL, St Peter WL, Ebben JP, et al. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis 2002; 40:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/13\">",
"      Mohanram A, Zhang Z, Shahinfar S, et al. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004; 66:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/14\">",
"      Chatterjee PK. Pleiotropic renal actions of erythropoietin. Lancet 2005; 365:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/15\">",
"      Chung SD, Huang KH, Liao CH, et al. Acute heart failure with elevated cardiac enzymes. Kidney Int 2007; 72:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/16\">",
"      Jungers P, Choukroun G, Oualim Z, et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001; 16:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/17\">",
"      Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/18\">",
"      Rossert J, Levin A, Roger SD, et al. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 2006; 47:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/19\">",
"      Dr&uuml;eke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/20\">",
"      Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/21\">",
"      Minutolo R, Conte G, Cianciaruso B, et al. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients. Nephrol Dial Transplant 2012; 27:2880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/22\">",
"      Provenzano R, Garcia-Mayol L, Suchinda P, et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol 2004; 61:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/23\">",
"      Piccoli A, Malagoli A, Komninos G, Pastori G. Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia. J Nephrol 2002; 15:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/24\">",
"      Provenzano R, Bhaduri S, Singh AK, PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol 2005; 64:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/25\">",
"      Benz R, Schmidt R, Kelly K, Wolfson M. Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease. Clin J Am Soc Nephrol 2007; 2:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/26\">",
"      McGowan T, Vaccaro NM, Beaver JS, et al. Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 2008; 3:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/27\">",
"      Pergola PE, Gartenberg G, Fu M, et al. A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia. Clin J Am Soc Nephrol 2010; 5:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/28\">",
"      Spinowitz B, Germain M, Benz R, et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clin J Am Soc Nephrol 2008; 3:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/29\">",
"      Lacson E Jr, Diaz-Buxo JA. The treatment of anemia in peritoneal dialysis patients. Clin Nephrol 2001; 56:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/30\">",
"      Muirhead N. Erythropoietic agents in peritoneal dialysis. Perit Dial Int 2005; 25:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/31\">",
"      Flanigan MJ, Rocco MV, Prowant B, et al. Clinical performance measures: the changing status of peritoneal dialysis. Kidney Int 2001; 60:2377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/32\">",
"      Obrador GT, Roberts T, St Peter WL, et al. Trends in anemia at initiation of dialysis in the United States. Kidney Int 2001; 60:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/33\">",
"      Navarro JF, Mora C, Mac&iacute;a M, Garc&iacute;a J. Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney Int 2002; 61:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/34\">",
"      Locatelli F, Aljama P, B&aacute;r&aacute;ny P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 Suppl 2:ii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/35\">",
"      Vadas O, Hartley O, Rose K. Characterization of new multimeric erythropoietin receptor agonists. Biopolymers 2008; 90:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/36\">",
"      Wrighton NC, Farrell FX, Chang R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996; 273:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/37\">",
"      Macdougall IC. Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia. Curr Opin Investig Drugs 2008; 9:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/38\">",
"      Fan Q, Leuther KK, Holmes CP, et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 2006; 34:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/39\">",
"      Woodburn KW, Fan Q, Winslow S, et al. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol 2007; 35:1201.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM297628.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/41\">",
"      Macdougall IC, Provenzano R, Sharma A, et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med 2013; 368:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/42\">",
"      Dr&uuml;eke TB. Anemia treatment in patients with chronic kidney disease. N Engl J Med 2013; 368:387.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm340895.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/44\">",
"      Johnson DL, Jolliffe LK. Erythropoietin mimetic peptides and the future. Nephrol Dial Transplant 2000; 15:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/45\">",
"      Sulowicz W, Locatelli F, Ryckelynck JP, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol 2007; 2:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/46\">",
"      Levin NW, Fishbane S, Ca&ntilde;edo FV, et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007; 370:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/47\">",
"      Klinger M, Arias M, Vargemezis V, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis 2007; 50:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33496/abstract/48\">",
"      Macdougall IC, Walker R, Provenzano R, et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol 2008; 3:337.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1952 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-1.234.2.38-C3DAD56939-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_45_33496=[""].join("\n");
var outline_f32_45_33496=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW OF TREATMENT OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      USE IN PREDIALYSIS PATIENTS WITH CHRONIC KIDNEY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Efficacy and benefits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Progression of renal failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Iron issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Whom to treat and target hemoglobin level",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      USE IN PERITONEAL DIALYSIS PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Iron issues and exclusion of non-renal anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Erythropoietin efficacy and dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Androgens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Peginesatide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Continuous Erythropoiesis Receptor Activator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=related_link\">",
"      Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23896?source=related_link\">",
"      Darbepoetin alfa for the management of anemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37752?source=related_link\">",
"      Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/8/9353?source=related_link\">",
"      Non-iron pharmacologic adjuvants to erythropoiesis stimulating agent therapy in dialysis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_45_33497="Percutaneous mitral balloon valvotomy for mitral stenosis";
var content_f32_45_33497=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Percutaneous mitral balloon valvotomy for mitral stenosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/45/33497/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/45/33497/contributors\">",
"     John D Carroll, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/45/33497/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/45/33497/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/45/33497/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/45/33497/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/45/33497/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/45/33497/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral stenosis (MS) is a disabling and eventually lethal disease. Untreated progressive disease can lead to significant symptoms (eg, dyspnea and fatigue) and serious complications (eg, pulmonary edema, systemic embolism, and pulmonary hypertension). The great majority of cases in adults are due to rheumatic heart disease, with symptoms usually appearing 16 to 40 years after the episode of acute rheumatic fever. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/29/18901?source=see_link\">",
"     \"Natural history of mitral stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although medical therapy can relieve symptoms, it does not affect the obstruction to flow. As a result, surgical commissurotomy and open valvuloplasty were, for many years, the only methods by which MS could be corrected. However, the development of percutaneous mitral balloon valvotomy (PMBV) by Inoue in 1984 and Lock in 1985 for the treatment of selected patients with MS has revolutionized the treatment of this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of PMBV, including comparison with surgery, and the management of patients with MS undergoing PMBV will be reviewed here. Issues directly related to the timing of intervention, and the medical and surgical management of MS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17480?source=see_link\">",
"     \"Surgical management of mitral stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4697?source=see_link\">",
"     \"Medical management and indications for intervention in mitral stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHOICE OF PMBV",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Rheumatic MS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are selected for PMBV on the basis of hemodynamic and echocardiographic criteria. PMBV is generally performed in chronically symptomatic patients, and may also include those who present emergently with cardiac arrest, cardiogenic shock, or pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Asymptomatic patients who plan on childbearing or major noncardiac surgery may also be candidates for this procedure. Prophylactic valvotomy for the prevention of systemic emboli or atrial fibrillation is not a firmly established criterion.",
"   </p>",
"   <p>",
"    When intervention is warranted, the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines generally recommended that PMBV is preferred to surgery if the valve morphology is favorable and the patient does not have left atrial thrombus or moderate to severe (3+ to 4+) mitral regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among asymptomatic patients, the main indication of PMBV was moderate to severe MS (valve area &le;1.5 cm2) and evidence of pulmonary hypertension at rest or with exercise (",
"    <a class=\"graphic graphic_algorithm graphicRef70612 \" href=\"UTD.htm?20/38/21103\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58960 \" href=\"UTD.htm?30/22/31084\">",
"     table 1",
"    </a>",
"    ). Similar recommendations were made in 2007 the European Society of Cardiology [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consensus guidelines have not addressed patient selection for PMBV to palliate symptoms in patients with multiple comorbidities or other conditions that preclude surgical valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/7\">",
"     7",
"    </a>",
"    ]. In these circumstances, PMBV is often performed (in the absence of left atrial thrombus or moderate to severe mitral regurgitation) despite moderate to advanced deformity of the valve that would otherwise be considered suboptimal or inappropriate for the procedure. Factors that may influence the decision to perform PMBV in such patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The goals of therapy in the palliative setting",
"     </li>",
"     <li>",
"      The role of MS in the patient's clinical condition",
"     </li>",
"     <li>",
"      Technical constraints",
"     </li>",
"     <li>",
"      The patient's own preference for symptom relief",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the United States, as many as 10 to 25 percent of patients undergoing PMBV fall into this palliative category.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Congenital MS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PMBV is primarily performed in patients with rheumatic MS. There is little experience with PMBV in congenital MS, where its efficacy is limited in patients with significant stenosis of the subvalvular apparatus and the catheterization procedure is potentially dangerous [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/4,8,9\">",
"     4,8,9",
"    </a>",
"    ]. PMBV should be considered only in selected patients at centers with established experience and skill [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mitral annular calcification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral annular calcification (MAC) is generally a benign process but may result in mitral regurgitation and more rarely mitral stenosis. It is commonly seen in the elderly. Annular calcification alone does not result in mitral stenosis but when calcification extends into the mitral inflow a gradient may be produced. MAC causing mitral stenosis is not amenable to balloon valvotomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/58/37801?source=see_link&amp;anchor=H36#H36\">",
"     \"Mitral annular calcification\", section on 'Mitral valve surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography is an essential screening procedure in patients who appear to be candidates for PMBV (",
"    <a class=\"graphic graphic_table graphicRef68079 \" href=\"UTD.htm?39/25/40347\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52663 \" href=\"UTD.htm?21/42/22187\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/4,10-12\">",
"     4,10-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Valvular anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of valvular and subvalvular deformity can be evaluated and the likelihood of a successful result after PMBV can be assessed by assigning a score of 0 to 4 for each of four factors [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The degree of leaflet rigidity",
"     </li>",
"     <li>",
"      The severity of leaflet thickening",
"     </li>",
"     <li>",
"      The amount of leaflet calcification",
"     </li>",
"     <li>",
"      The extent of subvalvular thickening and calcification",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The maximum score is 16; higher scores indicate more severe anatomic disease and a lower likelihood of a successful balloon valvotomy with durability.",
"   </p>",
"   <p>",
"    A similar scoring system may help to predict the development of severe mitral regurgitation after valvotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In a series of 117 patients undergoing valvotomy, those who developed severe mitral regurgitation had a significantly higher score compared to those who did not develop this complication (10.5 versus 8.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/14\">",
"     14",
"    </a>",
"    ]. When a total score of &ge;10 was used as a cut-off, the sensitivity, specificity, and positive and negative predictive values for predicting severe mitral regurgitation were 82, 91, 90, and 97 percent, respectively. This finding was reported from a single center and it is not the author's experience that advanced valve deformity predicts a higher risk of inducing severe mitral regurgitation unless the fused commissures are calcified.",
"   </p>",
"   <p>",
"    The echocardiographic score is also related to in-hospital costs. In one report, the mean in-hospital cost was much higher in patients with a score above 8 than in those with lower scores ($21,137 versus $7613) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/15\">",
"     15",
"    </a>",
"    ]. The cost increased by $2663 for every grade increase in the score.",
"   </p>",
"   <p>",
"    Another possibly effective approach for predicting outcome after valvotomy involves echocardiographic examination of the mitral valve commissures, since splitting of fused commissures is the primary mechanism by which PMBV produces a long-term therapeutic impact. Studies have examined the significance of calcification of the commissures as a predictor of procedural outcome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, 149 patients were followed for three years after PMBV. Patients with commissural calcium had a lower survival and a higher incidence of mitral valve replacement (MVR) (",
"      <a class=\"graphic graphic_figure graphicRef80604 \" href=\"UTD.htm?24/15/24829\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a subsequent review of 300 patients, the extent of commissural calcification was quantified on a scale of 0 to 4 by giving each half of the posteromedial and anterolateral commissure a score of 0 or 1 (maximum score 16) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/17\">",
"       17",
"      </a>",
"      ]. The commissural calcification grade was a significant predictor of achieving a mitral valve area of &gt;1.5 cm2 without mitral regurgitation, particularly in patients with an echo score &le;8.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings compare favorably to the predictive value of the echocardiographic scoring system. Thus, commissural calcium is an adjunct to the echocardiographic evaluation of mitral valve morphology.",
"   </p>",
"   <p>",
"    Intracardiac echocardiography (ICE) employs an ultrasound-tipped catheter inserted intravenously and manipulated within the heart (",
"    <a class=\"graphic graphic_figure graphicRef60589 \" href=\"UTD.htm?30/40/31375\">",
"     figure 2",
"    </a>",
"    ). Although not currently an accepted part of the diagnostic strategy for the evaluation of patients with mitral stenosis, one preliminary observations study suggests that ICE may detects more extensive subvalvular disease than suggested by TTE or TEE and therefore may improve patient selection for PMBV versus surgery (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73918 graphicRef82552 graphicRef59077 \" href=\"UTD.htm?25/56/26504\">",
"     image 1A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/18\">",
"     18",
"    </a>",
"    ]. This technique can also be used for monitoring during the valvotomy procedure (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Technique'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The results of echocardiography can be combined with other factors to improve patient selection. A logistic model was developed in a review of 1514 patients undergoing PMBV [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/19\">",
"     19",
"    </a>",
"    ]. Younger patients and those with evidence of less severe disease by echocardiography, estimated valve area, and effective balloon dilating area had a better outcome.",
"   </p>",
"   <p>",
"    While echocardiographic scoring systems may be of some benefit in predicting the outcome of PMBV, their practical clinical utility when considered in isolation is limited. The induction of severe mitral regurgitation and other sequelae can occur even in patients with \"ideal\" valves. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Postprocedural MR'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, PMBV is often performed with an expectation that as many as 25 to 35 percent of patients may not have an event-free five-year survival. Finally, in patients who are not surgical candidates, palliative PMBV may be necessary even in the face of poor echocardiographic scores.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Left atrial thrombus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of left atrial or left atrial appendage thrombus is a contraindication to PMBV because of the risk of dislodging the thrombus during the procedure. Such thrombi are not uncommon in patients with MS. The prevalence appears to be related in part to whether or not the patients have been treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . Thus, in two series of patients referred for PMBV, the prevalence of left atrial thrombus was 13 percent in a study from Scotland in which almost all patients had been treated with warfarin [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/20\">",
"     20",
"    </a>",
"    ] compared to 32 percent in a report from Thailand, which excluded patients who had been treated with warfarin more than 72 hours before study entry [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with the 2006",
"    <span class=\"nowrap\">",
"     AHA/ACC",
"    </span>",
"    valvular disease guideline and the 2008 American College of Chest Physicians (ACCP) guideline recommendation to perform preprocedural transesophageal echocardiography (TEE) to exclude left atrial thrombus in patients being considered for PBMV [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/4,22\">",
"     4,22",
"    </a>",
"    ]. If the preprocedural TEE reveals left atrial thrombus, we recommend postponement of the procedure and administration of anticoagulant therapy (target INR 3.0, range 2.5 to 3.5) until thrombus resolution is documented by repeat TEE [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/22\">",
"     22",
"    </a>",
"    ]. If left atrial thrombus does not resolve with anticoagulant therapy, we recommend that PMBV not be performed if surgery is feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/4,22\">",
"     4,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transesophageal echocardiography (TEE) is much more sensitive than transthoracic echocardiography (TTE) for the detection of left atrial thrombus. This difference was illustrated in a series of 474 patients undergoing mitral valve surgery in which the sensitivity and specificity of TTE were 32 and 94 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/23\">",
"     23",
"    </a>",
"    ]. In contrast, the sensitivity and specificity of TEE for left atrial appendage thrombi were 98 and 98 percent, and for left atrial cavity thrombi 81 and 99 percent. As a result, TEE is recommended prior to PMBV (",
"    <a class=\"graphic graphic_table graphicRef52663 \" href=\"UTD.htm?21/42/22187\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/4,24\">",
"     4,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=see_link\">",
"     \"Echocardiography in detection of intracardiac sources of embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients in whom left atrial thrombus is seen on TEE may be treated with six months of anticoagulation followed by repeat TEE to evaluate for resolution of thrombus. The frequency with which this occurs was assessed in a report of 219 patients from Thailand [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/21\">",
"     21",
"    </a>",
"    ]. Oral anticoagulation was initiated to maintain an INR of 2.0 to 3.0. At six months, thrombus was no longer detectable in 53 patients (24 percent). Variables predicting thrombus resolution included better NYHA functional class (I or II), thrombus size &le;1.6 cm2 and confined to the left atrial appendage, less marked left atrial spontaneous echocardiographic contrast, and maintenance of a mean INR &ge;2.5. Patients with all of these predictors had a 94 percent incidence of complete thrombus resolution.",
"   </p>",
"   <p>",
"    In a study from India of 66 patients with MS and left atrial thrombus, oral anticoagulation was given for up to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/25\">",
"     25",
"    </a>",
"    ]. Complete resolution of thrombus was seen on TEE in 22 patients (33 percent) and organization in 38 (58 percent); only six patients (9 percent) had no change in thrombus appearance.",
"   </p>",
"   <p>",
"    Some patients with left atrial appendage thrombus found on TEE immediately prior to planned PMBV are too symptomatic to wait six months. In such patients, a shorter duration of anticoagulation may be tried prior to repeat TEE. Surgical mitral valve repair or replacement with left atrial appendage ligation may need to be considered in patients unable to tolerate an adequate duration of anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21686?source=see_link&amp;anchor=H3#H3\">",
"     \"Nonpharmacologic therapy to prevent embolization in patients with atrial fibrillation\", section on 'Surgical LAA ligation or amputation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While improved imaging during PMBV, as with real-time 3D TEE, may enable more careful catheter manipulation in the LA, it remains impossible to guarantee that the catheter tip will not end up unintentionally in the LAA during some part of the procedure. Given the devastating nature of an embolic CVA from a LAA thrombus, it is hard to justify the potential risk of PMBV in the presence of thrombus when an alternative approach is possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;During cardiac catheterization, a transseptal puncture is used to gain access to the mitral valve from the left atrium. A single deflated balloon or a double-balloon is advanced from the venous circulation to the right atrium, across the interatrial septum to the left atrium, and across the stenotic mitral valve. Inflation and rapid deflation of the balloon opens the stenotic valve via separation of the fused commissures (",
"    <a class=\"graphic graphic_movie graphicRef75997 \" href=\"UTD.htm?35/46/36591\">",
"     movie 1",
"    </a>",
"    ). This mechanism is similar to that of surgical commissurotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/26\">",
"     26",
"    </a>",
"    ]. Fracture of calcific deposits in the leaflet tissue may also contribute to improved leaflet mobility and leaflet separation.",
"   </p>",
"   <p>",
"    In addition to direct measurement of the transmitral pressure gradient, the standard approach to monitoring PMBV is transthoracic echocardiography with measurement of mitral valve area and assessment of mitral regurgitant severity after each balloon dilation. The procedure is stopped when an adequate valve area has been achieved or if there is a significant increase in mitral regurgitant severity.",
"   </p>",
"   <p>",
"    Transesophageal echocardiography (TEE) can be performed during PMBV to guide the procedure and monitor for complications [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/12,27\">",
"     12,27",
"    </a>",
"    ]. However, TEE has the disadvantage that general anesthesia may be required due to the length of the procedure. Most centers use transthoracic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intracardiac echocardiography.",
"   </p>",
"   <p>",
"    Intracardiac echocardiography can delineate the extent of valvular deformity (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Valvular anatomy'",
"    </a>",
"    above) and may also be useful in visualizing several key steps of the valvotomy procedure, including [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transseptal puncture of the interatrial septum (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef73452 \" href=\"UTD.htm?1/62/2017\">",
"       image 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Exclusion of thrombus from the left atrial appendage",
"     </li>",
"     <li>",
"      Optimizing balloon placement across the valve orifice (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef53943 \" href=\"UTD.htm?41/8/42127\">",
"       image 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Initial assessment of the results of dilatation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disadvantages of this approach are increased cost and, with current transducers, an inability to accurately measure mitral valve area or adequately assess mitral regurgitation.",
"   </p>",
"   <p>",
"    It has been suggested that three-dimensional echocardiographic reconstruction from the TEE study may be of value [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/28\">",
"     28",
"    </a>",
"    ]. Real-time 3D TEE became commercially available in 2007 and is being used in some centers to guide PMBV. This enables improved visualization of catheter manipulations, a more comprehensive assessment of the mitral valve before and after PMBV, and a more visually intuitive guidance but improved outcomes from a 3D approach have not yet been reported. 3D TEE may identify commissural splitting and leaflet tears that are not visible on a 2-dimensional study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23146?source=see_link&amp;anchor=H11#H11\">",
"     \"Three-dimensional echocardiography\", section on 'Mitral valve'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Short-term",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early (immediate) results of PMBV are excellent. Most investigators report that the valve area increases from a critically stenotic value of 1.0 cm2 to approximately 2.0 cm2, a change that is associated with a rapid reduction in left atrial pressure (",
"    <a class=\"graphic graphic_figure graphicRef64660 \" href=\"UTD.htm?21/25/21919\">",
"     figure 3",
"    </a>",
"    ). This is smaller than the normal valve area of 3 to 5 cm2, but it is sufficient to produce substantial hemodynamic improvements including a decrease in left atrial pressure and the transmitral pressure gradient, a reduction in pulmonary artery pressure, and an increase in cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/1\">",
"     1",
"    </a>",
"    ]. An additional benefit is a reduction in left atrial stiffness, resulting in an increase in left atrial pump function in patients in sinus rhythm and an increase in left atrial reservoir function in those with atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Long-term",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twelve months after valvotomy, several hemodynamic parameters show continued improvement, including further reductions in pulmonary artery systolic pressure and increases in cardiac output. Pulmonary vascular resistance declines and normalizes in many patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/30\">",
"     30",
"    </a>",
"    ]. However, in a long-term follow-up of 561 patients, there was a progressive reduction in the mitral valve area which, by seven years, was &ge;0.3 cm2 in 27 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/31\">",
"     31",
"    </a>",
"    ]. In comparison, mild to moderate mitral regurgitation after the procedure did not progress in 81 percent and, when progression occurred, it was generally by one grade. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Postprocedural MR'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A review from the NHLBI Balloon Valvuloplasty Registry evaluated 736 patients over the age of 18 who were followed for four years [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The actuarial survival rate at one, two, three, and four years was 93, 90, 87, and 84 percent, respectively.",
"     </li>",
"     <li>",
"      The event free survival (freedom from death, mitral valve surgery or repeat PMBV) at one, two, three, and four years was 80, 71, 66, and 60 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with MS and pulmonary hypertension may develop functional tricuspid regurgitation. Successful PMBV with decrease in pulmonary artery pressures is associated with improvement in tricuspid regurgitation in some but not all patients. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'PMBV versus mitral valve replacement combined with tricuspid valve repair'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/9/149?source=see_link\">",
"     \"Etiology, clinical features, and evaluation of tricuspid regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Predictors of long-term outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term results are heavily dependent upon the clinical, hemodynamic, and echocardiographic features at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/5,31-38\">",
"     5,31-38",
"    </a>",
"    ]. Not surprisingly, there is a high mortality when emergent valvotomy is performed in patients with cardiogenic shock, cardiac arrest, or pulmonary edema refractory to medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/5\">",
"     5",
"    </a>",
"    ]. Among patients treated electively, independent predictors of longer event-free survival include less deformed valves, normal ventricular function, and better NYHA functional class (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/33\">",
"     33",
"    </a>",
"    ]. In a review of 146 patients, those who fulfilled all two to three of these criteria had five year event-free survival rates of 60 to 84 percent compared to 13 to 41 percent who fulfilled none or one of these criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These predictors have been confirmed by larger studies [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/31,32,35-38\">",
"     31,32,35-38",
"    </a>",
"    ]. In the above NHLBI review, for example, multivariate predictors of mortality were functional NYHA class IV (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 4",
"    </a>",
"    ), higher echocardiography deformity score, and higher postprocedural pulmonary artery systolic and left ventricular end-diastolic pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings were noted in a report of 879 patients who were followed for 12 years [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/37\">",
"     37",
"    </a>",
"    ]. Regression analysis identified the following as independent predictors of adverse events (death, mitral valve surgery, and repeat PMBV):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Echocardiographic score &gt;8, which was associated with lower success rates and smaller increases in mitral valve area",
"     </li>",
"     <li>",
"      Increasing age",
"     </li>",
"     <li>",
"      Prior surgical commissurotomy",
"     </li>",
"     <li>",
"      NYHA functional class IV",
"     </li>",
"     <li>",
"      Higher postprocedural pulmonary artery pressure",
"     </li>",
"     <li>",
"      Preprocedural mitral regurgitation &ge;2+",
"     </li>",
"     <li>",
"      Postprocedural mitral regurgitation &ge;3+",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with an echocardiographic score &le;8 had, at a follow-up of 12 years, significantly higher rates of patient survival (82 versus 57 percent in patients with a higher score) and total event-free survival (38 versus 22 percent). The results were virtually identical when limited to patients with successful PMBV.",
"   </p>",
"   <p>",
"    The importance of these risk factors probably explains observed discrepancies in clinical outcome for various patient populations. Studies from developing countries typically involve younger patients with lower echocardiographic scores, who therefore may have event-free survival rates at five to ten years of well over 75 percent (comparable to that seen with surgical commissurotomy). In contrast, North American patient series tend to involve older patients with more severe valvular deformity and calcification and consequently a much lower event-free survival rate [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with MS have atrial fibrillation (AF), which can adversely affect the short- and long-term outcome after surgical mitral commissurotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/39\">",
"     39",
"    </a>",
"    ]. The impact of AF on the results after PMBV was addressed in a study that compared the outcome of 355 patients with AF to 379 in normal sinus rhythm [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/40\">",
"     40",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with AF were older and more frequently presented with NYHA class IV heart failure, echocardiographic score &gt;8, calcified valves, and a history of previous commissurotomy.",
"     </li>",
"     <li>",
"      Procedural success was lower when AF was present (61 versus 76 percent with sinus rhythm) and in-hospital mortality was higher (3 versus 0.5 percent).",
"     </li>",
"     <li>",
"      The long-term outcome was poorer in those with AF compared to those with sinus rhythm, largely due to a smaller postprocedure mitral valve area (1.7 versus 2.0 cm2); after a 60 month follow-up, overall survival (68 versus 89 percent) and event-free survival (without death, repeat valvotomy, or mitral valve surgery; 32 versus 61 percent) were lower in the patients with AF.",
"     </li>",
"     <li>",
"      In those with AF, independent predictors of events were similar to those described above: severe postprocedure mitral regurgitation (&ge;3+), echocardiographic score &gt;8, and preprocedural NYHA class IV heart failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another report evaluated the efficacy of electrical cardioversion one month after PMBV in 71 patients with MS who had AF [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/41\">",
"     41",
"    </a>",
"    ]. Cardioversion was successful in 50 (71 percent); these patients were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    until the end of the study at one year. AF recurred in 24 (48 percent), and increased left atrial diameter was the only predictor of recurrence. The outcomes were best in the 43 percent of patients who had a left atrial diameter &lt;60 mm and no associated aortic valve disease; approximately two-thirds of these patients were in sinus rhythm at one year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Postprocedural MR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral regurgitation (MR) is a potential complication of PMBV [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/31,42\">",
"     31,42",
"    </a>",
"    ]. The frequency, causes, and natural history of significant postprocedural MR was evaluated in a follow-up study of 380 patients who underwent successful PMBV [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/42\">",
"     42",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant MR (more than mild) developed in 12.4 percent of patients.",
"     </li>",
"     <li>",
"      The most frequent mechanism (57 percent) was MR that originated at the site of successful commissurotomy. Noncommissural MR resulted from leaflet laceration or subchordal damage.",
"     </li>",
"     <li>",
"      The survival rate at eight years was not statistically different between those with and without MR (96 and 98 percent, respectively).",
"     </li>",
"     <li>",
"      The eight year event-free survival (absence of cardiac death, MVR, second PMBV, heart failure requiring admission or embolism) rate was significantly lower in patients with significant MR than in those without MR (48 versus 83 percent, respectively). Patients with commissural MR had a higher rate of event-free survival than those with noncommissural MR (63 versus 29 percent). The frequency of MVR in patients with commissural and noncommissural MR was 15 and 70 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term event-free survival after PMBV may be lower in elderly adults, largely due to more comorbidities (including coronary heart disease) and valve deformity and calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/1,32,43\">",
"     1,32,43",
"    </a>",
"    ]. Nevertheless, outcomes may still be satisfactory, particularly in patients with favorable valve morphology [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/7,32,43,44\">",
"     7,32,43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PMBV is also an effective, low-risk palliative treatment in elderly patients who have marked valvular and subvalvular degenerative changes that would normally require valve replacement, but are high risk candidates for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with MS who become pregnant are often seen in the developing world. In comparison, in developed countries, MS is often first diagnosed during pregnancy because of worsening symptoms induced by the hemodynamic burden of pregnancy. Some patients require prolonged bed rest and hospitalization but most can be managed with beta blockers and diuretics. If medical therapy is unsuccessful, PMBV is the preferred treatment if echocardiography does not show left atrial or left atrial appendage thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/45-49\">",
"     45-49",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Left atrial thrombus'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29447?source=see_link\">",
"     \"Pregnancy in women with mitral stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The preferred time for PMBV is in the 22 to 26 week gestational window that minimizes the radiation risks to the developing fetus. Although fetal survival is unlikely at this gestational age if emergent delivery is precipitated, the maternal and fetal risk is substantial if PMBV is delayed in patients with severe MS.",
"   </p>",
"   <p>",
"    The efficacy of PMBV was evaluated in a study of 45 pregnant women who underwent PMBV or surgical mitral valve commissurotomy for severe heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/45\">",
"     45",
"    </a>",
"    ]. The procedural success rate of PMBV was 95 percent. Improvement in symptoms was the same in both groups; however, fetal complications were less frequent and fetal and neonatal mortality were lower with PMBV (5 versus 38 percent with surgical commissurotomy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who have undergone successful PMBV, participation in sports should, as in patients with untreated lesions, be based upon the residual severity of MS or mitral regurgitation and the possible presence of left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/50\">",
"     50",
"    </a>",
"    ]. The capacity to exercise should be evaluated with an exercise test to at least the level of anticipated activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4697?source=see_link&amp;anchor=H3#H3\">",
"     \"Medical management and indications for intervention in mitral stenosis\", section on 'Physical activity and exercise'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the management of chronic mitral regurgitation\", section on 'Physical activity and exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Repeat PMBV",
"    </span>",
"    &nbsp;&mdash;&nbsp;After PMBV, up to 21 percent of patients develop recurrent heart failure due to mitral restenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/19,33\">",
"     19,33",
"    </a>",
"    ]. Although some of these patients undergo MVR, repeat PMBV is an alternative approach, especially in patients who are not good surgical candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. In a series of 36 patients with symptomatic MS who underwent repeat PMBV, the following results were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/52\">",
"     52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The immediate procedural success rate was 75 percent",
"     </li>",
"     <li>",
"      At one and three years, overall survival was 74 and 71 percent, respectively, and event-free survival was 61 and 47 percent, respectively",
"     </li>",
"     <li>",
"      Patients who had comorbid cardiac or noncardiac diseases had a much lower two year event-free survival compared to those without another disease (29 versus 86 percent) (",
"      <a class=\"graphic graphic_figure graphicRef65758 \" href=\"UTD.htm?15/6/15470\">",
"       figure 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Independent risk factors for event-free survival after repeat balloon valvotomy were the same as those for the first procedure and included preprocedural echocardiographic score and postprocedural mitral valve area, mitral regurgitation severity, and pulmonary artery pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Restenosis after surgical commissurotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;PMBV has been performed in patients who have developed mitral valve restenosis after previous commissurotomy. The immediate hemodynamic results and the long-term hemodynamics and outcome at 12 to 40 months appear to be similar to those seen with PMBV in unoperated MS [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/54-56\">",
"     54-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One report, for example, described 232 patients who underwent PMBV a mean of 16 years after surgical commissurotomy: 82 percent had good immediate results (valve area &ge;1.5 cm2 without more than grade 2 of 4 mitral regurgitation); one patient died (0.4 percent); and 4 percent had &gt;grade 2 mitral regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/56\">",
"     56",
"    </a>",
"    ]. After an eight year follow-up, 58 percent of those with good immediate results were in NYHA class I or II (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It should be kept in mind that patients selected for PMBV with restenosis after surgical commissurotomy are a subset without advanced deformity of the valve apparatus and without important mitral regurgitation. Many patients with restenosis after surgical commissurotomy are further along in the chronic scarring process and some have other valvular abnormalities. Such patients need surgery rather than PMBV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PMBV VERSUS SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical outcomes following PMBV have been compared with outcomes following surgical commissurotomy in randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/57-60\">",
"     57-60",
"    </a>",
"    ]. Fewer data are available comparing outcomes following PMBV versus mitral valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     PMBV versus surgical commissurotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical and hemodynamic results of PMBV have been compared with the different forms of surgical correction: closed surgical valvotomy, and open and closed surgical commissurotomy. In each of these trials, the outcome after PMBV was as good or better than after surgery in patients who are candidates for valvotomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17480?source=see_link\">",
"     \"Surgical management of mitral stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PMBV was compared to closed surgical commissurotomy in two prospective randomized trials of young patients in South Africa and India [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/57,58\">",
"       57,58",
"      </a>",
"      ]. In both reports, the results of percutaneous techniques compared favorably with those obtained surgically.",
"     </li>",
"     <li>",
"      PMBV was compared to open surgical commissurotomy in a randomized trial of 60 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/59\">",
"       59",
"      </a>",
"      ]. Mitral valve area increased initially from a mean of 0.9 to 2.1 cm2 in the PMBV group and from 0.9 to 2.0 cm2 in those treated with surgery. After three years, however, patients treated with percutaneous valvotomy had a higher average valve area (2.4 versus 1.8 cm2) and a greater likelihood of NYHA functional class I (72 versus 57 percent). No serious complications were reported during the initial hospitalization, but an atrial septal defect was present in four patients in the PMBV group; one of these patients died 2.5 years after the valvotomy.",
"     </li>",
"     <li>",
"      PMBV was compared to open surgical commissurotomy, and closed surgical commissurotomy in 90 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/60\">",
"       60",
"      </a>",
"      ]. The short- and long-term outcomes were not as good with closed surgical commissurotomy. Mitral valve area increased more after PMBV (0.9 to 2.2 cm2) and open commissurotomy (0.9 to 2.0 cm2) than closed commissurotomy (0.9 to 1.6 cm2), and residual MS was less (0 versus 27 percent with the closed procedure). There was no early or late mortality or thromboembolism among the three groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After a seven year follow-up, echocardiographic mitral valve area was significantly less with closed commissurotomy compared to the other procedures (1.3 versus 1.8 cm2) and the restenosis rate was higher (37 versus 7 percent). At late follow-up, closed commissurotomy was also associated with fewer patients in NYHA class I (33 versus 87 and 90 percent) and a higher likelihood of requiring a reintervention (50 versus 10 and 7 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     PMBV versus mitral valve replacement combined with tricuspid valve repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvement in associated tricuspid regurgitation occurs in some but not all patients following successful PMBV. A retrospective study of patients with severe MS and severe tricuspid regurgitation (TR) compared outcomes in 48 patients undergoing PMBV versus 44 patients undergoing mitral valve replacement combined with tricuspid valve (TV) repair [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/61\">",
"     61",
"    </a>",
"    ]. During 57 months of follow-up, 2 deaths occurred in each group and there were 7 cases of heart failure requiring surgical intervention in the PMBV group only (event rate difference was borderline significant, p=0.05). Severe TR was improved to mild or absent TR in 98 percent of the surgery group and in 46 percent of the PMBV group. These findings suggest mitral valve replacement combined with TV repair may produce better outcomes in patients with severe MS and severe TR than PMBV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Preference for PMBV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The salutary long-term results, lower costs, and the avoidance of thoracotomy make PMBV the treatment of choice in patients with MS who have the following features (",
"    <a class=\"graphic graphic_table graphicRef58960 \" href=\"UTD.htm?30/22/31084\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Moderate to severe MS",
"     </li>",
"     <li>",
"      Pliable, noncalcified mitral valves",
"     </li>",
"     <li>",
"      Symptoms or, if asymptomatic, pulmonary artery hypertension",
"     </li>",
"     <li>",
"      The absence of left atrial thrombus or moderate to severe mitral regurgitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, patients who are too old or frail for surgery or those with severe valve deformities might consider percutaneous valvotomy as a palliative procedure in the absence of left atrial thrombus or moderate to severe mitral regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Echocardiography is an essential screening procedure to assist in identifying patients who will benefit from PMBV. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Choice of PMBV'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Indications for surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;A surgical approach with mitral valve repair, if possible, or valve replacement is indicated in patients with moderate to severe symptomatic MS who have moderate to severe (3+-4+) mitral regurgitation or left atrial thrombus that persists despite anticoagulation or who have valve morphology that is not favorable for PMBV (",
"    <a class=\"graphic graphic_table graphicRef76806 \" href=\"UTD.htm?27/32/28172\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef55549 graphicRef68528 \" href=\"UTD.htm?2/53/2897\">",
"     algorithm 2A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef79292 graphicRef57298 \" href=\"UTD.htm?24/6/24674\">",
"     algorithm 3A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Open surgical commissurotomy is usually preferred in patients with severe subvalvular or calcific disease, when left atrial thrombus precludes safe balloon valvotomy. Closed commissurotomy is still performed in some developing nations where cost and perhaps lack of PMBV capability are continuing problems [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33497/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17480?source=see_link\">",
"     \"Surgical management of mitral stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery is generally preferred in patients with congenital MS because of the often complex anatomy. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Congenital MS'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17480?source=see_link&amp;anchor=H4#H4\">",
"     \"Surgical management of mitral stenosis\", section on 'Congenital MS'",
"    </a>",
"    .) Surgery may also be preferred in patients with both severe MS and severe TR. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'PMBV versus mitral valve replacement combined with tricuspid valve repair'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to refer a patient for PMBV versus surgical valve replacement is influenced by the expected long-term benefits of the various treatment options, the anticipated risks of surgery, and the goals of treatment. The precision of outcome prediction is somewhat limited with PMBV, thereby introducing greater uncertainty than in many other medical conditions. As a result, careful preprocedure consultation with an open discussion with the patient and family is especially important.",
"   </p>",
"   <p>",
"    It is also important to recognize that, particularly in young patients, eventual surgical valve replacement is likely to be necessary in the long term, even for very successful percutaneous procedures. Nevertheless, the benefit of postponing surgery for as long as a decade or more can be significant, depending upon the individual patient.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/1\">",
"      Carroll JD, Feldman T. Percutaneous mitral balloon valvotomy and the new demographics of mitral stenosis. JAMA 1993; 270:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/2\">",
"      Inoue K, Owaki T, Nakamura T, et al. Clinical application of transvenous mitral commissurotomy by a new balloon catheter. J Thorac Cardiovasc Surg 1984; 87:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/3\">",
"      Lock JE, Khalilullah M, Shrivastava S, et al. Percutaneous catheter commissurotomy in rheumatic mitral stenosis. N Engl J Med 1985; 313:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/4\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/5\">",
"      Lokhandwala YY, Banker D, Vora AM, et al. Emergent balloon mitral valvotomy in patients presenting with cardiac arrest, cardiogenic shock or refractory pulmonary edema. J Am Coll Cardiol 1998; 32:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/6\">",
"      Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/7\">",
"      Sutaria N, Elder AT, Shaw TR. Long term outcome of percutaneous mitral balloon valvotomy in patients aged 70 and over. Heart 2000; 83:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/8\">",
"      Moore P, Adatia I, Spevak PJ, et al. Severe congenital mitral stenosis in infants. Circulation 1994; 89:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/9\">",
"      Chen GY, Tseng CD, Chiang FT, et al. Congenital mitral stenosis: challenge of percutaneous transvenous mitral commissurotomy. Int J Cardiol 1997; 60:99.",
"     </a>",
"    </li>",
"    <li>",
"     Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline for the clinical application of echocardiography www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/11\">",
"      Wilkins GT, Weyman AE, Abascal VM, et al. Percutaneous balloon dilatation of the mitral valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J 1988; 60:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/12\">",
"      Abascal VM, Wilkins GT, O'Shea JP, et al. Prediction of successful outcome in 130 patients undergoing percutaneous balloon mitral valvotomy. Circulation 1990; 82:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/13\">",
"      Padial LR, Freitas N, Sagie A, et al. Echocardiography can predict which patients will develop severe mitral regurgitation after percutaneous mitral valvulotomy. J Am Coll Cardiol 1996; 27:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/14\">",
"      Padial LR, Abascal VM, Moreno PR, et al. Echocardiography can predict the development of severe mitral regurgitation after percutaneous mitral valvuloplasty by the Inoue technique. Am J Cardiol 1999; 83:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/15\">",
"      Eisenberg MJ, Ballal R, Heidenreich PA, et al. Echocardiographic score as a predictor of in-hospital cost in patients undergoing percutaneous balloon mitral valvuloplasty. Am J Cardiol 1996; 78:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/16\">",
"      Cannan CR, Nishimura RA, Reeder GS, et al. Echocardiographic assessment of commissural calcium: a simple predictor of outcome after percutaneous mitral balloon valvotomy. J Am Coll Cardiol 1997; 29:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/17\">",
"      Sutaria N, Northridge DB, Shaw TR. Significance of commissural calcification on outcome of mitral balloon valvotomy. Heart 2000; 84:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/18\">",
"      Green NE, Hansgen AR, Carroll JD. Initial clinical experience with intracardiac echocardiography in guiding balloon mitral valvuloplasty: technique, safety, utility, and limitations. Catheter Cardiovasc Interv 2004; 63:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/19\">",
"      Iung B, Cormier B, Ducimeti&egrave;re P, et al. Immediate results of percutaneous mitral commissurotomy. A predictive model on a series of 1514 patients. Circulation 1996; 94:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/20\">",
"      Shaw TR, Northridge DB, Sutaria N. Mitral balloon valvotomy and left atrial thrombus. Heart 2005; 91:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/21\">",
"      Silaruks S, Thinkhamrop B, Kiatchoosakun S, et al. Resolution of left atrial thrombus after 6 months of anticoagulation in candidates for percutaneous transvenous mitral commissurotomy. Ann Intern Med 2004; 140:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/22\">",
"      Salem DN, O'Gara PT, Madias C, et al. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:593S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/23\">",
"      Kaymaz C, Ozdemir N, Kirma C, et al. Location, size and morphological characteristics of left atrial thrombi as assessed by echocardiography in patients with rheumatic mitral valve disease. Eur J Echocardiogr 2001; 2:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/24\">",
"      Manning WJ, Reis GJ, Douglas PS. Use of transoesophageal echocardiography to detect left atrial thrombi before percutaneous balloon dilatation of the mitral valve: a prospective study. Br Heart J 1992; 67:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/25\">",
"      Kandpal B, Garg N, Anand KV, et al. Role of oral anticoagulation and inoue balloon mitral valvulotomy in presence of left atrial thrombus: a prospective serial transesophageal echocardiographic study. J Heart Valve Dis 2002; 11:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/26\">",
"      Inoue K, Feldman T. Percutaneous transvenous mitral commissurotomy using the Inoue balloon catheter. Cathet Cardiovasc Diagn 1993; 28:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/27\">",
"      Kronzon I, Tunick PA, Schwinger ME, et al. Transesophageal echocardiography during percutaneous mitral valvuloplasty. J Am Soc Echocardiogr 1989; 2:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/28\">",
"      Applebaum RM, Kasliwal RR, Kanojia A, et al. Utility of three-dimensional echocardiography during balloon mitral valvuloplasty. J Am Coll Cardiol 1998; 32:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/29\">",
"      Stefanadis C, Dernellis J, Stratos C, et al. Effects of balloon mitral valvuloplasty on left atrial function in mitral stenosis as assessed by pressure-area relation. J Am Coll Cardiol 1998; 32:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/30\">",
"      Fawzy ME, Mimish L, Sivanandam V, et al. Immediate and long-term effect of mitral balloon valvotomy on severe pulmonary hypertension in patients with mitral stenosis. Am Heart J 1996; 131:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/31\">",
"      Hernandez R, Ba&ntilde;uelos C, Alfonso F, et al. Long-term clinical and echocardiographic follow-up after percutaneous mitral valvuloplasty with the Inoue balloon. Circulation 1999; 99:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/32\">",
"      Dean LS, Mickel M, Bonan R, et al. Four-year follow-up of patients undergoing percutaneous balloon mitral commissurotomy. A report from the National Heart, Lung, and Blood Institute Balloon Valvuloplasty Registry. J Am Coll Cardiol 1996; 28:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/33\">",
"      Cohen DJ, Kuntz RE, Gordon SP, et al. Predictors of long-term outcome after percutaneous balloon mitral valvuloplasty. N Engl J Med 1992; 327:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/34\">",
"      Wang A, Krasuski RA, Warner JJ, et al. Serial echocardiographic evaluation of restenosis after successful percutaneous mitral commissurotomy. J Am Coll Cardiol 2002; 39:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/35\">",
"      Meneveau N, Schiele F, Seronde MF, et al. Predictors of event-free survival after percutaneous mitral commissurotomy. Heart 1998; 80:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/36\">",
"      Iung B, Garbarz E, Michaud P, et al. Late results of percutaneous mitral commissurotomy in a series of 1024 patients. Analysis of late clinical deterioration: frequency, anatomic findings, and predictive factors. Circulation 1999; 99:3272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/37\">",
"      Palacios IF, Sanchez PL, Harrell LC, et al. Which patients benefit from percutaneous mitral balloon valvuloplasty? Prevalvuloplasty and postvalvuloplasty variables that predict long-term outcome. Circulation 2002; 105:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/38\">",
"      Stefanadis CI, Stratos CG, Lambrou SG, et al. Retrograde nontransseptal balloon mitral valvuloplasty: immediate results and intermediate long-term outcome in 441 cases--a multicenter experience. J Am Coll Cardiol 1998; 32:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/39\">",
"      Rihal CS, Schaff HV, Frye RL, et al. Long-term follow-up of patients undergoing closed transventricular mitral commissurotomy: a useful surrogate for percutaneous balloon mitral valvuloplasty? J Am Coll Cardiol 1992; 20:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/40\">",
"      Leon MN, Harrell LC, Simosa HF, et al. Mitral balloon valvotomy for patients with mitral stenosis in atrial fibrillation: immediate and long-term results. J Am Coll Cardiol 1999; 34:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/41\">",
"      Krittayaphong R, Chotinaiwatarakul C, Phankingthongkum R, et al. One-year outcome of cardioversion of atrial fibrillation in patients with mitral stenosis after percutaneous balloon mitral valvuloplasty. Am J Cardiol 2006; 97:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/42\">",
"      Kim MJ, Song JK, Song JM, et al. Long-term outcomes of significant mitral regurgitation after percutaneous mitral valvuloplasty. Circulation 2006; 114:2815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/43\">",
"      Shaw TR, Sutaria N, Prendergast B. Clinical and haemodynamic profiles of young, middle aged, and elderly patients with mitral stenosis undergoing mitral balloon valvotomy. Heart 2003; 89:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/44\">",
"      Krasuski RA, Warner JJ, Peterson G, et al. Comparison of results of percutaneous balloon mitral commissurotomy in patients aged &gt; or = 65 years with those in patients aged &lt; 65 years. Am J Cardiol 2001; 88:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/45\">",
"      de Souza JA, Martinez EE Jr, Ambrose JA, et al. Percutaneous balloon mitral valvuloplasty in comparison with open mitral valve commissurotomy for mitral stenosis during pregnancy. J Am Coll Cardiol 2001; 37:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/46\">",
"      Iung B, Cormier B, Elias J, et al. Usefulness of percutaneous balloon commissurotomy for mitral stenosis during pregnancy. Am J Cardiol 1994; 73:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/47\">",
"      Patel JJ, Mitha AS, Hassen F, et al. Percutaneous balloon mitral valvotomy in pregnant patients with tight pliable mitral stenosis. Am Heart J 1993; 125:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/48\">",
"      Sivadasanpillai H, Srinivasan A, Sivasubramoniam S, et al. Long-term outcome of patients undergoing balloon mitral valvotomy in pregnancy. Am J Cardiol 2005; 95:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/49\">",
"      Fawzy ME, Kinsara AJ, Stefadouros M, et al. Long-Term outcome of mitral balloon valvotomy in pregnant women. J Heart Valve Dis 2001; 10:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/50\">",
"      Bonow RO, Cheitlin MD, Crawford MH, Douglas PS. Task Force 3: valvular heart disease. J Am Coll Cardiol 2005; 45:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/51\">",
"      Iung B, Garbarz E, Michaud P, et al. Immediate and mid-term results of repeat percutaneous mitral commissurotomy for restenosis following earlier percutaneous mitral commissurotomy. Eur Heart J 2000; 21:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/52\">",
"      Pathan AZ, Mahdi NA, Leon MN, et al. Is redo percutaneous mitral balloon valvuloplasty (PMV) indicated in patients with post-PMV mitral restenosis? J Am Coll Cardiol 1999; 34:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/53\">",
"      Fawzy ME, Hassan W, Shoukri M, et al. Immediate and long-term results of mitral balloon valvotomy for restenosis following previous surgical or balloon mitral commissurotomy. Am J Cardiol 2005; 96:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/54\">",
"      Lau KW, Ding ZP, Gao W, et al. Percutaneous balloon mitral valvuloplasty in patients with mitral restenosis after previous surgical commissurotomy. A matched comparative study. Eur Heart J 1996; 17:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/55\">",
"      Gupta S, Vora A, Lokhandwalla Y, et al. Percutaneous balloon mitral valvotomy in mitral restenosis. Eur Heart J 1996; 17:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/56\">",
"      Iung B, Garbarz E, Michaud P, et al. Percutaneous mitral commissurotomy for restenosis after surgical commissurotomy: late efficacy and implications for patient selection. J Am Coll Cardiol 2000; 35:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/57\">",
"      Patel JJ, Shama D, Mitha AS, et al. Balloon valvuloplasty versus closed commissurotomy for pliable mitral stenosis: a prospective hemodynamic study. J Am Coll Cardiol 1991; 18:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/58\">",
"      Turi ZG, Reyes VP, Raju BS, et al. Percutaneous balloon versus surgical closed commissurotomy for mitral stenosis. A prospective, randomized trial. Circulation 1991; 83:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/59\">",
"      Reyes VP, Raju BS, Wynne J, et al. Percutaneous balloon valvuloplasty compared with open surgical commissurotomy for mitral stenosis. N Engl J Med 1994; 331:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/60\">",
"      Ben Farhat M, Ayari M, Maatouk F, et al. Percutaneous balloon versus surgical closed and open mitral commissurotomy: seven-year follow-up results of a randomized trial. Circulation 1998; 97:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33497/abstract/61\">",
"      Song H, Kang DH, Kim JH, et al. Percutaneous mitral valvuloplasty versus surgical treatment in mitral stenosis with severe tricuspid regurgitation. Circulation 2007; 116:I246.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8161 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-220.255.2.157-02C9EFC5AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_45_33497=[""].join("\n");
var outline_f32_45_33497=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHOICE OF PMBV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Rheumatic MS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Congenital MS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mitral annular calcification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Valvular anatomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Left atrial thrombus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Short-term",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Long-term",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Predictors of long-term outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Postprocedural MR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Repeat PMBV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Restenosis after surgical commissurotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PMBV VERSUS SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PMBV versus surgical commissurotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PMBV versus mitral valve replacement combined with tricuspid valve repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Preference for PMBV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Indications for surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8161\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8161|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/38/21103\" title=\"algorithm 1\">",
"      Management asymptomatic MS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?1/50/1839\" title=\"algorithm 2A\">",
"      Rx MS mild symptoms I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?26/17/26910\" title=\"algorithm 2B\">",
"      Rx MS mild symptoms II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?38/6/39023\" title=\"algorithm 3A\">",
"      Rx MS moderate severe sx I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?34/16/35086\" title=\"algorithm 3B\">",
"      Rx MS moderate severe sx II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8161|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/29/1489\" title=\"diagnostic image 1A\">",
"      ICE normal MV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/14/37088\" title=\"diagnostic image 1B\">",
"      ICE mitral stenosis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/12/24768\" title=\"diagnostic image 1C\">",
"      ICE mitral stenosis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/62/2017\" title=\"diagnostic image 2\">",
"      ICE transseptal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/8/42127\" title=\"diagnostic image 3\">",
"      ICE PMBV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8161|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/15/24829\" title=\"figure 1\">",
"      Commisural calcium in MS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/40/31375\" title=\"figure 2\">",
"      ICE technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/25/21919\" title=\"figure 3\">",
"      Valvotomy in mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/6/15470\" title=\"figure 4\">",
"      Outcome repeat valvuloplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8161|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?35/46/36591\" title=\"movie 1\">",
"      Mitral valvuloplasty using the Inoue balloon catheter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8161|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/22/31084\" title=\"table 1\">",
"      Percutaneous mitral valvotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/25/40347\" title=\"table 2\">",
"      Echo in mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/42/22187\" title=\"table 3\">",
"      TEE in mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 4\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/32/28172\" title=\"table 5\">",
"      ACC AHA surgery mitral stenosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=related_link\">",
"      Echocardiography in detection of intracardiac sources of embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/9/149?source=related_link\">",
"      Etiology, clinical features, and evaluation of tricuspid regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4697?source=related_link\">",
"      Medical management and indications for intervention in mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/58/37801?source=related_link\">",
"      Mitral annular calcification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/29/18901?source=related_link\">",
"      Natural history of mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21686?source=related_link\">",
"      Nonpharmacologic therapy to prevent embolization in patients with atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/51/33593?source=related_link\">",
"      Overview of the management of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29447?source=related_link\">",
"      Pregnancy in women with mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17480?source=related_link\">",
"      Surgical management of mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23146?source=related_link\">",
"      Three-dimensional echocardiography",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_45_33498="Treatment of Behets disease";
var content_f32_45_33498=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of Beh&ccedil;et&rsquo;s disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/45/33498/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/45/33498/contributors\">",
"     Ellison L Smith, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/45/33498/contributors\">",
"     Yusuf Yazici, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/45/33498/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/45/33498/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/45/33498/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/45/33498/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/45/33498/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beh&ccedil;et&rsquo;s disease is an inflammatory disease characterized by recurrent oral aphthous ulcers and numerous potential systemic manifestations. These include genital ulcers, ocular disease, skin lesions, neurologic disease, vascular disease, and arthritis.",
"   </p>",
"   <p>",
"    Most clinical manifestations of Beh&ccedil;et&rsquo;s disease are believed to be due to vasculitis. Among the systemic vasculitides, Beh&ccedil;et's disease is remarkable for its ability to involve blood vessels of all sizes&mdash;small, medium, and large&mdash;on both the arterial and venous sides of the circulation.",
"   </p>",
"   <p>",
"    The treatment of Beh&ccedil;et&rsquo;s disease will be reviewed here. The pathogenesis, clinical manifestations, and diagnosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28874?source=see_link\">",
"     \"Pathogenesis of Beh&ccedil;et&rsquo;s disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF THE BEH&Ccedil;ET&rsquo;S LITERATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The literature on the treatment of Beh&ccedil;et&rsquo;s disease consists primarily of case reports and small case series, with few follow-up studies to confirm findings of preliminary reports and few randomized clinical trials.",
"   </p>",
"   <p>",
"    In a systematic review from the Cochrane Database of trials conducted up until 1998, only 10 single- or double-blind trials fit the inclusion criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/1\">",
"     1",
"    </a>",
"    ]. The authors noted a lack of comparability across trials that precluded the pooling of data. The robustness of their analysis was hampered by the small number of studies.",
"   </p>",
"   <p>",
"    The main results of the Cochrane analysis cast some doubt on the efficacy of several classic treatments for Beh&ccedil;et&rsquo;s disease, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and glucocorticoids for eye disease and colchicine for arthritis. Protective effects for eye involvement were confirmed for both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Since 1998, there have been only a small number of advances in the quality of the Beh&ccedil;et&rsquo;s disease literature. These include significant benefit in randomized trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    for mucocutaneous disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/2\">",
"     2",
"    </a>",
"    ] and the introduction of anti-TNF-alpha therapy. Most current approaches with other medications are dictated primarily by extrapolation of the use of certain medications from their efficacy in other inflammatory conditions. A systematic review of the literature through 2006 is the basis for the 2008 European League Against Rheumatism (EULAR) recommendations for the management of Beh&ccedil;et&rsquo;s disease. Our approach is generally consistent with those recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first part of this topic will review the pharmacologic agents that have been employed in Beh&ccedil;et&rsquo;s disease, with references and short summaries of the available literature on each medication. The second part is devoted to the discussion of therapeutic approaches to specific Beh&ccedil;et&rsquo;s disease manifestations, grouped according to the organ system that is involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     AVAILABLE PHARMACOLOGIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medications commonly employed in the treatment of Beh&ccedil;et&rsquo;s disease are listed below, along with some of the data supporting or refuting their utility. Treatment approaches for specific clinical presentations of Beh&ccedil;et&rsquo;s disease are discussed later in this topic. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Treatment by organ system'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are the mainstay of Beh&ccedil;et&rsquo;s disease treatment for patients with moderately severe to severe disease. High doses may be required for acute life- or organ-threatening disease; lower doses are appropriate for less acute or severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although general clinical experience with Beh&ccedil;et&rsquo;s disease and extrapolation from the treatment of related conditions suggest that glucocorticoids are effective for this disorder, no high-quality placebo-controlled trials of glucocorticoids have been performed. Some data suggest that the efficacy of glucocorticoids varies according to the regimen and route of administration [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/7\">",
"     7",
"    </a>",
"    ]. High dose pulse treatment (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    1 gram administered intravenously for one to five days, mostly commonly for three days) is often used for progressive, severe, organ or life-threatening disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1464079\">",
"    <span class=\"h2\">",
"     Colchicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    has long been used for the treatment of Beh&ccedil;et&rsquo;s, particularly for mucocutaneous disease. Clinical studies of colchicine have shown mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/1,2,8-10\">",
"     1,2,8-10",
"    </a>",
"    ]. Colchicine therapy was associated with significant reductions in the number of arthritic joints in all patients and in genital ulcers and erythema nodosum in women [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/2\">",
"     2",
"    </a>",
"    ]. A randomized crossover trial in 169 patients showed significant improvement in overall disease activity as well as oral aphthosis, genital aphthosis, pseudofolliculitis and erythema nodosum in treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients may develop significant gastrointestinal intolerance of colchicine if the medication is taken at total doses higher than 1.5",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    is one of the few medications evaluated in a randomized, double-blind, placebo-controlled trial in Beh&ccedil;et&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/12\">",
"     12",
"    </a>",
"    ]. In this trial, 73 patients with Beh&ccedil;et&rsquo;s disease were treated with glucocorticoids and either azathioprine (2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) or placebo. The follow-up period was two years.",
"   </p>",
"   <p>",
"    The primary results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 25 patients without eye disease at the outset, there were fewer new cases of ocular involvement with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (one versus eight).",
"     </li>",
"     <li>",
"      Among the 48 patients with eye disease, there were fewer cases of hypopyon uveitis (1 versus 15).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      therapy was also associated with less frequent oral ulcers, genital ulcers, and arthritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In an eight year follow-up of 57 patients (five had died and 11 were lost to follow-up), a reduction in visual acuity and vision loss were significantly less frequent in those assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , despite similar treatment for patients in both groups after the two year trial ended [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    was beneficial for many of 157 consecutive patients (52 percent complete responders, 41 percent partial responders) treated for active posterior uveitis or panuveitis due to Beh&ccedil;et's [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Before the initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , genetic testing for the presence of thiopurine methyltransferase may be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link&amp;anchor=H4#H4\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Pharmacogenetics and TPMT testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    (1 to 2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, orally; or 1 g or 0.75 to 1",
"    <span class=\"nowrap\">",
"     g/m2",
"    </span>",
"    by monthly infusion IV) is felt to be an effective agent for neurologic and vascular Beh&ccedil;et&rsquo;s disease, although published data are limited and not of high quality.",
"   </p>",
"   <p>",
"    A systematic review from the Cochrane database concluded that there was insufficient evidence to support the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in the treatment of Beh&ccedil;et&rsquo;s disease, particularly the ocular manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/1\">",
"     1",
"    </a>",
"    ]. In a single masked trial comparing cyclophosphamide (1 g IV bolus monthly) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) in 23 patients with active and potentially reversible uveitis, visual acuity at six months improved with cyclosporine but not cyclophosphamide [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/15\">",
"     15",
"    </a>",
"    ]. Lack of benefit on ocular disease was noted in another report [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, an open trial comparing intravenous pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    to pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    for uveitis found benefit only with cyclophosphamide [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/16\">",
"     16",
"    </a>",
"    ] and some observational studies have suggested benefit for ocular and central nervous system disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in Beh&ccedil;et&rsquo;s disease has been evaluated primarily for the treatment of ocular, mucocutaneous, and articular disease. About one-half of patients treated for mucocutaneous or ocular disease have improved [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/15,18,19\">",
"     15,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is generally used in combination with glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/20\">",
"     20",
"    </a>",
"    ] and often, in severe or resistant cases, with other immunosuppressive drugs agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/8\">",
"     8",
"    </a>",
"    ]. Many patients who respond to cyclosporine have recurrent disease after discontinuation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations illustrate the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in patients with ocular disease, a manifestation for which the meta-analysis from the Cochrane database concluded that the available data supported benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) was compared to monthly intravenous pulse",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (1000 mg) in a randomized, single-masked trial of 23 patients with active uveitis [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/15\">",
"       15",
"      </a>",
"      ]. More improvement in visual acuity was seen in the cyclosporine group at six months, but similar improvement was noted in the two groups at two years.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      was compared to treatment with glucocorticoids or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      in a randomized trial of 40 patients with ocular Beh&ccedil;et&rsquo;s disease [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/21\">",
"       21",
"      </a>",
"      ]. Ocular disease was controlled more effectively by cyclosporine, but articular, cutaneous, and mucocutaneous disease manifestations were not.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    may be less effective for central nervous system (CNS) disease. A retrospective review of 117 patients with Beh&ccedil;et&rsquo;s disease, ten of whom developed new CNS involvement, found more CNS episodes (6 of 21) in those on cyclosporine, than in those on other agents (0 of 175) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/22\">",
"     22",
"    </a>",
"    ]. EULAR guidelines caution against the use of cyclosporine in patients with CNS disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    are common. Approximately one-half of patients with Beh&ccedil;et&rsquo;s disease treated with this agent had an elevation in the serum creatinine concentration that was reversible when the cyclosporine dose was reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/19\">",
"     19",
"    </a>",
"    ]. Hypertension is common with cyclosporine treatment. Neurotoxicity is also frequently seen, and may be difficult to differentiate from disease-related neurologic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    , a calcineurin inhibitor similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , has a similar side effect profile but may be tolerated better by some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Anti-TNF-alpha therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agents that inhibit the actions of tumor necrosis factor (TNF)-alpha may ameliorate Beh&ccedil;et&rsquo;s disease activity. Beneficial effects have been noted with both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , and there is evidence that infliximab may be more effective [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/5,25\">",
"     5,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Infliximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of observational studies have suggested efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    for the treatment of inflammatory eye disease, major organ involvement, and other symptoms in Beh&ccedil;et&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/26-40\">",
"     26-40",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an uncontrolled series, 13 patients were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      (5 or 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously for four doses at weeks 0, 2, 6, and 10) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. A decrease in the frequency of episodes of uveitis was observed during the 14 weeks of treatment (one versus a mean of approximately four episodes in the 14 weeks prior to treatment).",
"     </li>",
"     <li>",
"      In an open prospective study, patients with relapsed Beh&ccedil;et&rsquo;s ocular inflammation were given a single",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      infusion of 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      while continuing their prior therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/35\">",
"       35",
"      </a>",
"      ]. Most patients responded rapidly and all improved by day 28. By day 28, vitritis and retinitis had resolved in 100 percent, retinal vasculitis in 94 percent, cystoid macular edema in 90 percent, and visual acuity in 100 percent. Fifteen of these patients subsequently received infliximab at 4, 8, 16, and 24 weeks. Complete remission occurred in 60 percent; mild relapses responded to increased steroid therapy; three patients with retinitis responded to repeat infusion and subsequent increased frequency of infusions every 6 weeks. Visual acuity was improved.",
"     </li>",
"     <li>",
"      In two reports, 11 patients with sight-threatening uveitis were treated with a single infusion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/26,41\">",
"       26,41",
"      </a>",
"      ]. All of the patients responded quickly. In one of the series, remission of ocular inflammation was apparent within 24 hours, complete suppression was seen at seven days, and three showed improved visual acuity [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/26\">",
"       26",
"      </a>",
"      ]. In the second study, orogenital inflammation, synovitis, thrombophlebitis, and gastrointestinal lesions also improved, and most were subsequently controlled on other immunosuppressive agents [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One study reported benefit from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      (starting at 5",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      in 12 patients with ocular Beh&ccedil;et's who had not responded to other therapies [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/42\">",
"       42",
"      </a>",
"      ]. The mean duration of follow-up was 36 months. All patients reached remission, seven did not require other immunosuppressive agents, nine were able to stop systemic glucocorticoids, and visual acuity was stable or improved in all patients. Treatment was discontinued in two patients because of adverse events.",
"     </li>",
"     <li>",
"      The addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      did not result in additional benefit in a study of 14 patients with ocular Beh&ccedil;et's [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/43\">",
"       43",
"      </a>",
"      ]. The reduced frequency of ocular attacks did not differ between infliximab-treated patients who received colchicine and those who did not.",
"     </li>",
"     <li>",
"      Benefit from treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg/infusion)",
"      </span>",
"      was shown in a study of 50 patients with Beh&ccedil;et's (n = 36) or idiopathic posterior segment uveitis (n = 14) who had not responded adequately to at least one immunosuppressive drug [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/44\">",
"       44",
"      </a>",
"      ]. The mean follow-up period was 37 months. Patients were treated at onset with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg/day),",
"      </span>",
"      which was rapidly tapered. Complete and partial responses were seen in 68 and 22 percent of patients, respectively, with a significant reduction in ocular attacks and cystoid macular edema, compared with baseline, and with stable or improved visual acuity in all patients. Responses were not observed in 10 percent of the patients; these patients withdrew from the study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The preponderance of experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    is in rheumatoid arthritis and inflammatory bowel disease. Adverse effects of infliximab are discussed in more detail in the context of these diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of biologic agents in the rheumatic diseases\", section on 'Infliximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"     \"Infliximab in Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Etanercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    may ameliorate the mucosal and skin manifestations of Beh&ccedil;et&rsquo;s disease. This was illustrated in a randomized trial in which 40 patients with mucocutaneous disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arthritis were assigned to etanercept (25 mg subcutaneously twice a week) or placebo injections for four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following significant benefits were noted with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More patients remained free of oral ulcers (45 percent versus 5 percent).",
"     </li>",
"     <li>",
"      More patients remained free of nodular skin lesions (85 versus 25 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, the proportion of patients with genital ulcers, the mean number of swollen joints, and the mean scores for papulopustular skin lesions were not significantly different between the two groups.",
"   </p>",
"   <p>",
"    This trial did not address the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    on more serious clinical manifestations of Beh&ccedil;et&rsquo;s disease (eg, vascular disease and uveitis). The authors noted that more economical approaches to managing skin and mucosal disease should be considered before contemplating anti-TNF therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1464191\">",
"    <span class=\"h3\">",
"     Adalimumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of small studies have shown benefit with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    treatment. Eleven male patients with ocular Beh&ccedil;et's disease all showed at least some improvement in one case series [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/46\">",
"     46",
"    </a>",
"    ]. Seventeen of 69 patients who failed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    were treated with adalimumab, and 12 of 17 had a good response [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/47\">",
"     47",
"    </a>",
"    ]. Other small studies have also shown effectiveness with adalimumab treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Interferon alfa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon alfa-2a and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29576?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    (generally given 3 to 19 million units three times weekly) have been beneficial for mucocutaneous, ocular, articular, and neurologic disease in a number of case reports and case series [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/50-61\">",
"     50-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2004 systematic review of 32 original articles and four abstracts included 338 patients treated with interferon alfa-2a or alfa-2b [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/62\">",
"     62",
"    </a>",
"    ]. The primary findings were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Partial or complete responses were seen in 86 percent of the patients with mucocutaneous symptoms, 96 percent of those with arthritis, and 94 percent of those with uveitis. Higher doses of interferon were more effective and produced longer remissions.",
"     </li>",
"     <li>",
"      Many uveitis responders had failed a number of other immunosuppressive agents, and interferon therapy led to long term remissions in some patients.",
"     </li>",
"     <li>",
"      Combination therapy with glucocorticoids and other agents was common. In such studies, it is difficult to impute efficacy for the interferon agent.",
"     </li>",
"     <li>",
"      Partial and complete mucocutaneous responses occurred with similar frequency with interferon alfa-2a and alfa-2b.",
"     </li>",
"     <li>",
"      Relapse often followed cessation of therapy. Toxicities consisted mostly of flu-like symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Benefit with mucocutaneous disease or arthritis was shown in a randomized trial of 50 patients in which interferon alfa-2a significantly decreased the duration and pain of oral ulcers as well as the frequency of genital ulcers and papulopustular lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/55\">",
"     55",
"    </a>",
"    ]. The mean frequency and duration of erythema nodosum-like lesions, thrombophlebitis, and articular symptoms also decreased, but not in a statistically significant fashion.",
"   </p>",
"   <p>",
"    Among the 23 patients in the interferon alfa-2a group, 15 responded to treatment (2 complete and 13 partial responses); in comparison, the 21 patients in the placebo group had three partial responses. Thus, interferon alfa-2a appears effective in Beh&ccedil;et&rsquo;s disease, particularly for mucocutaneous manifestations.",
"   </p>",
"   <p>",
"    Observational studies support benefit from interferon alfa-2a in patients with ocular involvement. In a small study that included a longer follow-up period, nine Beh&ccedil;et&rsquo;s patients (15 eyes) with panuveitis or retinitis were treated with interferon alfa-2a and followed for a mean of 69 months [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/56\">",
"     56",
"    </a>",
"    ]. Eight of the nine patients were able to discontinue treatment. Visual acuity was improved in ten eyes and unchanged in five.",
"   </p>",
"   <p>",
"    In a case series of 50 patients with resistant uveitis, treatment consisted of interferon alfa-2a (6 million units daily for 14 days) and high-dose glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/57\">",
"     57",
"    </a>",
"    ]. The results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ninety-two percent of patients improved, which was evident in many patients within one month of initiating interferon therapy.",
"     </li>",
"     <li>",
"      The disease activity score at one year was improved compared to baseline, despite",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      tapering.",
"     </li>",
"     <li>",
"      Seventeen patients (33 percent) were off treatment and disease-free at a mean of 30 months observation. Other patients required maintenance therapy at a dose of 3 million units three times weekly. Genital ulcerations, arthritis, and skin lesions responded better than aphthous ulcers [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a retrospective study of 53 patients with severe Beh&ccedil;et's uveitis treated with interferon alfa followed for a mean of six years, 98 percent responded to treatment, 89 percent could discontinue treatment after remission, and 43 percent needed a second treatment course. Ocular disease remained in remission in 50 percent of patients at 46 months. Beh&ccedil;et's disease activity score decreased in follow-up, but some extra-ocular manifestations persisted in many patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies have also shown benefit in patients with Beh&ccedil;et's uveitis that is refractory to other treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;A trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil for the mucocutaneous manifestations of Beh&ccedil;et&rsquo;s was terminated due to lack of efficacy in the first six patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/67\">",
"     67",
"    </a>",
"    ]. There are case reports of benefit in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Thalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized clinical trial has been performed of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    as monotherapy for Beh&ccedil;et&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/69\">",
"     69",
"    </a>",
"    ]. In this trial, 96 patients were randomly assigned into one of three treatment groups: thalidomide 300",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    thalidomide 100",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    or placebo. The groups were followed for 24 weeks, with the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A complete response occurred in two of the 32 patients receiving 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      ; in five of the 31 patients receiving 300",
"      <span class=\"nowrap\">",
"       mg/day;",
"      </span>",
"      and in none of the 32 patients receiving placebo.",
"     </li>",
"     <li>",
"      The suppressive effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      with either dosage was evident at four weeks for oral ulcers and at eight weeks for genital ulcers and follicular lesions.",
"     </li>",
"     <li>",
"      The effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      persisted during treatment but diminished rapidly once therapy was discontinued.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With respect to possible adverse effects, both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    dosages were associated with increases in the number of erythema nodosum lesions during the first eight weeks of treatment. In addition, polyneuropathy developed in four patients treated with thalidomide.",
"   </p>",
"   <p>",
"    In summary, the therapeutic impact of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    in Beh&ccedil;et&rsquo;s disease is modest at best. Only a minority of thalidomide-treated patients responded to treatment, and some manifestations of disease (erythema nodosum) actually worsened. In addition, 7 percent of the thalidomide-treated patients developed peripheral neuropathy, a condition that is often irreversible.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    should be restricted to physicians experienced in the management of Beh&ccedil;et&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/70\">",
"     70",
"    </a>",
"    ]. Despite possible benefits, thalidomide is difficult to obtain, available as an investigational agent only (in most countries), carries a significant risk of neuropathy, and is generally reserved for resistant disease in patients who will observe strict contraceptive practices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1464279\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a randomized pilot trial of 20 patients with Beh&ccedil;et's retinal vasculitis and edema resistant to cytotoxic treatment, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    was more effective than treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and prednisolone [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data available regarding the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    , intravenous immunoglobulin, plasmapheresis, antibiotics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    (Campath 1-H),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    , antimalarials, rebamipide, hematopoietic stem cell transplantation (autologous, or derived from allogeneic bone marrow or umbilical cord blood), and granulocytopheresis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/52,72-84\">",
"     52,72-84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT BY ORGAN SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beh&ccedil;et&rsquo;s disease is a protean illness that includes manifestations with a broad range of disease severity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Minor disease manifestations that interfere significantly with patients' quality of life but do not threaten vital organ function. Examples of minor disease manifestations are arthritis and mucocutaneous disease.",
"     </li>",
"     <li>",
"      Major disease manifestations that may lead to the dysfunction of major organs and even to death. These include certain ocular and neurological manifestations, as well as complications of large-vessel arteritis and venous thrombotic disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following discussion of treatment approaches focuses on specific disease features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Arthritis",
"     </li>",
"     <li>",
"      Mucocutaneous manifestations",
"     </li>",
"     <li>",
"      Ocular disease",
"     </li>",
"     <li>",
"      Neurologic disease",
"     </li>",
"     <li>",
"      Gastrointestinal disease",
"     </li>",
"     <li>",
"      Renal disease",
"     </li>",
"     <li>",
"      Large artery involvement",
"     </li>",
"     <li>",
"      Venous thrombotic events",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evidence supporting the efficacy of particular approaches is presented above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The non-deforming arthritis characteristic of Beh&ccedil;et&rsquo;s disease is seldom the determinant of the level of therapy. When present, joint symptoms are usually accompanied by other manifestations of disease that dictate the intensity of treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       Colchicine",
"      </a>",
"      &mdash; The results of a controlled trial suggest that colchicine is effective for the arthritis of Beh&ccedil;et&rsquo;s disease [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/2\">",
"       2",
"      </a>",
"      ]. The dose employed in that study ranged from 1 to 2",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      administered in divided doses.",
"     </li>",
"     <li>",
"      Nonsteroidal antiinflammatory drugs &mdash; Residual joint complaints may respond to nonsteroidal antiinflammatory drugs (NSAIDs). There is no consensus among experts about a preferred NSAID for this indication.",
"     </li>",
"     <li>",
"      Glucocorticoids &mdash; Joint complaints not controlled by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      usually require low-dose glucocorticoids, with continuous efforts to maintain the minimally effective dose.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      is an appropriate starting dose for the arthritis of Beh&ccedil;et&rsquo;s disease, but if continuous therapy is required 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      should be the target dose, as this dose balances well the efficacy and long-term side effects of glucocorticoids.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      &mdash; A randomized demonstrated benefit from azathioprine in patients with arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/12\">",
"       12",
"      </a>",
"      ]. The primary use is as a glucocorticoid-sparing agent.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      is sometimes utilized for arthritis in the dose and fashion used in rheumatoid arthritis, but has not been well-studied. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link\">",
"       \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immunosuppressive agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and interferon alfa may be effective for arthritis associated with Beh&ccedil;et&rsquo;s disease. When employed, they are often used for other indications and in combination with glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/6,8\">",
"     6,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Mucocutaneous manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mucocutaneous manifestations of Beh&ccedil;et&rsquo;s disease include oral aphthae, genital ulcers that are identical in appearance to the oral lesions, and a variety of other skin findings (eg, acneiform lesions, erythema nodosum, pyoderma gangrenosum). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Oral aphthae and genital ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral ulcers in Beh&ccedil;et&rsquo;s disease, the sine qua non of this condition, often do not respond sufficiently to topical treatments and require systemic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Topical treatments &mdash; Topical anesthetics are generally ineffective in Beh&ccedil;et&rsquo;s disease. Topical glucocorticoid preparations are more likely to relieve ulcer-related pain. For isolated oral aphthae, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      acetonide cream (0.1 percent in Orabase). This should be applied three to four times daily and be used until pain from the ulcer ceases. Potent topical corticosteroids may be used for genital ulcers. Topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"       sucralfate",
"      </a>",
"      <span class=\"nowrap\">",
"       1g/5mL",
"      </span>",
"      four times daily as a mouthwash reduced pain, frequency and healing time in a randomized controlled trial for oral ulcers in Beh&ccedil;et&rsquo;s [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/82\">",
"       82",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"       Pimecrolimus",
"      </a>",
"      improved healing time in a randomized trial of 90 patients with genital aphthous ulcers [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intralesional glucocorticoids &mdash; Intralesional glucocorticoid preparations for large ulcers should be employed in collaboration with a dermatologist. A typical preparation is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      (5 to 10",
"      <span class=\"nowrap\">",
"       mg/mL).",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       Colchicine",
"      </a>",
"      &mdash; Data on the effects of colchicine for patients with minor oral ulcers or genital lesions are mixed [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/2,9,10\">",
"       2,9,10",
"      </a>",
"      ]. Some patients develop significant gastrointestinal intolerance of colchicine if the medication is taken at total doses higher than 1.5",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      Systemic glucocorticoids &mdash; When isolated oral aphthae or genital ulcers are refractory to topical glucocorticoids and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      or when multiple lesions are present,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      should be employed. An appropriate starting dose for mucocutaneous disease in the absence of other disease manifestations is 15",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      with tapering of the prednisone dose to 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      after one week and discontinuation of prednisone entirely over a two to three week period, assuming that the aphthae are no longer symptomatic.",
"      <br/>",
"      <br/>",
"      Patients with recurrent oral aphthae may require longer periods of maintenance treatment with low-dose prednisone (eg, 5",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"     </li>",
"     <li>",
"      Other immunosuppressive medications &mdash; If a daily",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose of more than 10 mg is required to control oral aphthae and genital lesions or if the adverse effects of prednisone are intolerable even at lower doses, an alternative immunosuppressive medication should be employed. Options in the order of preference include:",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day improved oral and genital ulceration in a randomized, double-blind, placebo controlled trial [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Azathioprine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anti-TNF-alpha agents (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      ) have been beneficial for mucocutaneous disease in a number of reports and one randomized trial [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/45\">",
"       45",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Anti-TNF-alpha therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in divided doses) was superior to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      in the management of ulceration in a controlled study [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/87\">",
"       87",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cyclosporine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interferon alfa decreased the frequency of oral aphthae and genital ulcers in a randomized, double-blind, placebo-controlled trial [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/55\">",
"       55",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Interferon alfa'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       Thalidomide",
"      </a>",
"      &mdash; The effectiveness of thalidomide for oral and genital ulceration is reviewed above [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/69,88\">",
"       69,88",
"      </a>",
"      ]. Given the generally greater efficacy of other agents for mucocutaneous Beh&ccedil;et&rsquo;s disease and the risk of peripheral neuropathy with thalidomide, thalidomide is seldom used for this indication in practice. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Thalidomide'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Other skin lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the exception of erythema nodosum and pyoderma gangrenosum, most other cutaneous manifestations of Beh&ccedil;et&rsquo;s disease (acneiform and papulopustular lesions, nodules, superficial thrombophlebitis, and palpable purpura) respond well to the more moderate measures discussed above, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    and low to moderate doses of glucocorticoids.",
"   </p>",
"   <p>",
"    The usual approach to cutaneous disease in Beh&ccedil;et&rsquo;s is to begin with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    for mild manifestations (1 to 2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in divided doses) and to institute",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (up to 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    initially) for lesions that are refractory to colchicine. Prednisone doses maintained between 5 and 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    are usually sufficient to control most skin manifestations of Beh&ccedil;et&rsquo;s disease.",
"   </p>",
"   <p>",
"    Erythema nodosum and pyoderma gangrenosum require special consideration.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erythema nodosum &mdash; In contrast to the erythema nodosum associated with sarcoidosis, inflammatory bowel disease, and other systemic inflammatory illnesses, erythema nodosum in Beh&ccedil;et&rsquo;s disease often represents a medium-vessel vasculitis [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/89\">",
"       89",
"      </a>",
"      ]. This accounts for the fact that the Beh&ccedil;et&rsquo;s-associated lesions often undergo ulceration. Because of the possibility of vasculitis underlying the clinical presentation of erythema nodosum, clinicians should consider moving quickly to glucocorticoids and other immunosuppressive medications if",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      is ineffective. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13130?source=see_link&amp;anchor=H26#H26\">",
"       \"Erythema nodosum\", section on 'Behcet's disease'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Confirmation of the presence of a medium-vessel vasculitis through biopsy or by ulceration of the erythema nodosum lesions is an indication for systemic glucocorticoid treatment combined with another immunosuppressive agent. In this setting, we suggest as initial therapy the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (40 to 60 mg PO daily) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (50 mg PO daily). The prednisone dose is maintained at its initial level for one month and then tapered off over three to four months. Azathioprine is increased as tolerated over four to six weeks to a daily dose of 2.5",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"      Before the initiation of azathioprine, we suggest genetic testing for the presence of thiopurine methyltransferase. Treatment, particularly the swiftness of the prednisone taper, should be dictated by the clinical response. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link&amp;anchor=H4#H4\">",
"       \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Pharmacogenetics and TPMT testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pyoderma gangrenosum &mdash; Pyoderma gangrenosum associated with Beh&ccedil;et&rsquo;s disease is often complicated by the pathergy phenomenon. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\", section on 'Cutaneous lesions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Just as sterile needle pricks of the skin lead to the development of cutaneous pustules at the site of trauma, the debridement of cutaneous lesions in Beh&ccedil;et&rsquo;s disease can exacerbate pyoderma gangrenosum and lead to local expansion. Thus, extensive debridement of pyoderma gangrenosum in Beh&ccedil;et&rsquo;s disease is discouraged.",
"   </p>",
"   <p>",
"    The treatment of pyoderma gangrenosum is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10202?source=see_link\">",
"     \"Pyoderma gangrenosum: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Ocular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular lesions are treated according to their severity [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/90\">",
"     90",
"    </a>",
"    ]. The two most common ocular manifestations, anterior and posterior uveitis, have significantly different therapeutic implications. However, isolated anterior uveitis is rare in Beh&ccedil;et&rsquo;s disease. The more common clinical scenario is pan-uveitis. Intermediate and posterior uveitis cannot be assessed reliably without the use of a slit lamp. Referral to an ophthalmologist is appropriate for all patients with Beh&ccedil;et&rsquo;s disease suspected of having uveitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\", section on 'Ocular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Anterior uveitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anterior uveitis of Beh&ccedil;et&rsquo;s disease is generally treated with topical glucocorticoids and a dilating drop such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    (0.25 percent) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/34/24100?source=see_link\">",
"     cyclopentolate",
"    </a>",
"    (1 percent). The dilating drop relieves pain due to spasm of the muscles controlling the pupil, and also helps prevent the formation of posterior synechiae that may interfere with the function of the pupil. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10407?source=see_link&amp;anchor=H5#H5\">",
"     \"Uveitis: Treatment\", section on 'Initial treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Failure to use a mydriatic (dilating) agent promptly may lead to the development of pupillary distortion, caused by the formation of scar tissue between the iris and lens.",
"   </p>",
"   <p>",
"    Patients whose anterior uveitis is not controlled with topical glucocorticoids may require a short-term period of systemic glucocorticoid therapy. Assuming no other organ system involvement that requires higher doses, we recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at an initial dose of 40 mg PO daily. The prednisone may be tapered to discontinuation over one month, assuming prompt disease control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Posterior uveitis and other major disease manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posterior uveitis (inflammation in the uveal tract that is posterior to the lens) in Beh&ccedil;et&rsquo;s disease constitutes a serious threat to vision and requires intensive immunosuppression. The combination of high-dose glucocorticoids and another immunosuppressive agent (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ) is required.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoid use in posterior uveitis &mdash; Systemic glucocorticoids help reduce the acute inflammatory features of serious end-organ disease, but disease activity tends to recur or progress if glucocorticoids are used without other immunosuppressive therapy. Depending upon the severity of disease, we generally start",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for one month, with tapering thereafter as tolerated). Initial pulse therapy with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      for three days) is sometimes used empirically for sight-threatening disease [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/5,6,91\">",
"       5,6,91",
"      </a>",
"      ]. Intraocular",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      may be beneficial for panuveitis for two to six months [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/92\">",
"       92",
"      </a>",
"      ]. Glucocorticoids are used together with another agent, usually",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      Choice of a second immunosuppressive agent &mdash; Azathioprine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      are all employed in the treatment of posterior uveitis related to Beh&ccedil;et&rsquo;s disease. Data to strongly support the use of any of these medications over the others is lacking. We and others prefer to use azathioprine together with glucocorticoids for initial therapy, based upon the limited available data, its adverse event profile, and experience with its use in Beh&ccedil;et&rsquo;s disease [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/4,12\">",
"       4,12",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Azathioprine reduced the risk of uveitis recurrence and vision loss in a randomized trial, with sustained benefit following treatment with azathioprine noted on long-term follow-up at seven years [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/13\">",
"       13",
"      </a>",
"      ]. The typical dose of azathioprine for this indication is 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. Treatment is begun at 50",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      after testing for thiopurine methyltransferase alleles. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link&amp;anchor=H4#H4\">",
"       \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Pharmacogenetics and TPMT testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Refractory or severe disease &mdash; In patients without an adequate response or with severe disease, we add a TNF inhibitor, most commonly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      . Severe eye disease can be defined as greater than two lines of drop in visual acuity on a",
"      <span class=\"nowrap\">",
"       10/10",
"      </span>",
"      scale",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      retinal disease, such as retinal vasculitis or macular involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/4\">",
"       4",
"      </a>",
"      ]. Infliximab is generally used together with another immunosuppressive agent (usually",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      in Beh&ccedil;et&rsquo;s disease, where the latter drug has been used extensively).",
"      <br/>",
"      <br/>",
"      There have been no randomized trials of infliximab in Beh&ccedil;et&rsquo;s disease. However, efficacy in posterior uveitis has been suggested by regimens in which infliximab is given at a dose of 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      at 0, 4, 8, 16, and 24 weeks or 0, 2, 6, and every 8 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. These regimens are similar to that used for treatment of patients with moderately to severely active Crohn's disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link&amp;anchor=H18#H18\">",
"       \"Infliximab in Crohn's disease\", section on 'Dose'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Other agents as outlined above may be used in refractory cases.",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      (2 to 5",
"      <span class=\"nowrap\">",
"       mg/kg/day)",
"      </span>",
"      can be efficacious in patients with Beh&ccedil;et&rsquo;s disease with posterior uveitis, and may be used together with glucocorticoids and azathioprine as an alternative to infliximab [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/15,20,21\">",
"       15,20,21",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cyclosporine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interferon alfa-2a may be of benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/65,66\">",
"       65,66",
"      </a>",
"      ]. Patients with retinal vasculitis or ocular disease refractory to the combination of glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      may respond to treatment with interferon alfa-2a alone [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/57,62,93,94\">",
"       57,62,93,94",
"      </a>",
"      ]. Leukopenia is a significant risk when interferon alfa-2a is used with azathioprine [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/93\">",
"       93",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Interferon alfa'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      has also shown benefit in a small trial in patients with severe ocular manifestations resistant to cytotoxic agents [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/71\">",
"       71",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      may be employed in refractory cases in which disease activity warrants the risk of treatment.",
"      <br/>",
"      <br/>",
"      Finally,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      , and other anti-TNF agents may be considered despite the paucity of published in trials in the absence of other treatment options.",
"     </li>",
"     <li>",
"      Duration of therapy &mdash; Some form of immunosuppressive therapy is continued for at least 18 to 24 months in patients with posterior uveitis, depending upon the clinical response and severity of disease. During this time, glucocorticoid therapy is tapered as tolerated, and immunosuppressive agents with the greater potential for toxicity (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ) are discontinued in favor of medications that are likely to be safer (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ). Some patients require one or more immunosuppressive agents indefinitely to sustain remission. In our experience, up to approximately 50 percent of patients may be able to completely discontinue immunosuppressive therapy without recurrence of eye disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Neurologic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with ocular disease, there is a range of disease severity among the neurologic lesions. Focal parenchymal lesions, encephalitis, and medium-vessel vasculitis are all potentially life-threatening disease manifestations that should be treated in the same manner as posterior uveitis. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Posterior uveitis and other major disease manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Aseptic meningitis may occur intermittently in patients with Beh&ccedil;et&rsquo;s disease. In the absence of other disease manifestations demanding more intensive therapy, most cases of aseptic meningitis respond promptly to high doses of glucocorticoids (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, to a maximum of 80",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    This",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose can be tapered to discontinuation over one month. Frequent recurrences of aseptic meningitis may herald the need for long-term maintenance therapy with another immunosuppressive agent. In this setting, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Azathioprine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The treatment of cerebral sinus thrombosis is discussed below. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Venous thrombosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Gastrointestinal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discrete ulcerations may be observed in the terminal ileum, cecum, and ascending colon. The presence of significant gastrointestinal involvement in Beh&ccedil;et&rsquo;s disease signals the need for glucocorticoid therapy plus an additional agent designed to limit the long-term need for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    For gastrointestinal ulceration in Beh&ccedil;et&rsquo;s disease, we suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoids plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      &mdash; Treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      should be instituted in consultation with a gastroenterologist, who can assess the extent and severity of gastrointestinal disease. Typical starting doses for prednisone for gastrointestinal Beh&ccedil;et&rsquo;s disease are 0.5 to 1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/95\">",
"       95",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The initial dose is usually maintained for at least one month or until symptoms improve before the institution of a taper, which is designed to decrease the daily dose to 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      within two to three months. Subsequent tapering to discontinuation over an additional two months may proceed if disease control is maintained.",
"      <br/>",
"      <br/>",
"      Azathioprine should be instituted at essentially the same time as prednisone. The typical dose of azathioprine is 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. Treatment is begun at 50",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      after testing for thiopurine methyltransferase alleles and increased at weekly intervals until the target dose is achieved (usually within one month). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link&amp;anchor=H4#H4\">",
"       \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Pharmacogenetics and TPMT testing'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Azathioprine should be maintained for at least six months, with periodic reassessments of its need and serial endoscopies conducted by the gastroenterologist as appropriate.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      &mdash; Several reports suggest successful treatment of intestinal Beh&ccedil;et&rsquo;s disease with infliximab using regimens approximating those approved for the treatment of inflammatory bowel disease [",
"      <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/96,97\">",
"       96,97",
"      </a>",
"      ]. The typical schedule of administration is 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      at 0, 2, and 6 weeks, followed by 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 8 weeks.",
"     </li>",
"     <li>",
"      Though not well-studied,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      is sometimes used to treat gastrointestinal disease in the same fashion as it is used in the treatment of inflammatory bowel disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link\">",
"       \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although urinary abnormalities (proteinuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hematuria) occur in approximately 10 percent of patients, serious renal lesions are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/98\">",
"     98",
"    </a>",
"    ]. In a review of 4212 patients, glomerulonephritis was diagnosed by renal biopsy in only seven cases. This would represent a minimum incidence of disease.",
"   </p>",
"   <p>",
"    The spectrum of renal diseases associated was illustrated in a review of 159 patients with renal Beh&ccedil;et&rsquo;s disease: AA (secondary) amyloidosis was present in 69, glomerulonephritis in 51, vascular disease (mostly renal arterial aneurysms) in 35, and interstitial nephritis in 4 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/99\">",
"     99",
"    </a>",
"    ]. Among the patients with glomerulonephritis, there was a spectrum of lesions ranging from IgA nephropathy to crescentic glomerulonephritis.",
"   </p>",
"   <p>",
"    Treatment of Beh&ccedil;et&rsquo;s renal disease varies with the lesion and may already be part of therapy for other manifestations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with minimal or mild nephritis (eg, hematuria, protein excretion &lt;500 to 1000",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      and normal creatinine) may require no specific therapy, although monitoring is warranted for possible disease progression.",
"     </li>",
"     <li>",
"      Patients with AA amyloidosis, which results from chronic inflammation, require therapy for the Beh&ccedil;et&rsquo;s disease. The preferred therapy is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      (1.0 to 1.2 mg PO daily), which treats both the Beh&ccedil;et&rsquo;s disease and the amyloidosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23383?source=see_link&amp;anchor=H5#H5\">",
"       \"Treatment of secondary (AA) amyloidosis\", section on 'Colchicine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The treatment of renal artery aneurysms is discussed in the next section. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Large artery disease'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With respect to clinically important glomerulonephritis, there are only small case series and retrospective reviews to guide therapy in patients with Beh&ccedil;et&rsquo;s disease. Given the vasculitic nature of Beh&ccedil;et&rsquo;s disease, a reasonable approach is to extrapolate from the treatment efficacy of medications used in granulomatosis with polyangiitis (Wegener&rsquo;s), particularly in patients with focal necrotizing lesions or crescentic glomerulonephritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H12#H12\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Daily oral cyclophosphamide and glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to these specific therapies, all patients with persistent proteinuric renal disease should be treated with general therapies to slow disease progression, such as angiotensin converting enzyme inhibitors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angiotensin II receptor blockers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the management of chronic kidney disease in adults\", section on 'Slowing the rate of progression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Large artery disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial involvement in Beh&ccedil;et&rsquo;s disease is uncommon but can lead to dilatations and aneurysms of medium- and large-sized arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/99-101\">",
"     99-101",
"    </a>",
"    ]. In a review cited above of 159 patients with renal involvement, 35 had renal vascular disease, mostly renal arterial aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/99\">",
"     99",
"    </a>",
"    ]. These complications may require combined medical and surgical or interventional radiology treatments.",
"   </p>",
"   <p>",
"    The medical approach involves high-dose glucocorticoids and another immunosuppressive agent, typically",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/6\">",
"     6",
"    </a>",
"    ]. The approach with both of these medications for this indication is as described above in the treatment of posterior uveitis. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Posterior uveitis and other major disease manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Small studies also report improvement with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is ideal to perform surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    interventional radiology procedures when the patient's disease is quiescent. However, it is often necessary to intervene urgently for enlarging or ruptured aneurysms or organ-threatening ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outcomes in large-vessel arterial disease were illustrated in a retrospective review of 25 patients, included seven with occlusions, three with aneurysms, and fifteen with both [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/104\">",
"     104",
"    </a>",
"    ]. The main findings were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High dose glucocorticoids did not improve occlusive disease and may have contributed to one fatal infection.",
"     </li>",
"     <li>",
"      Aneurysms had a worse prognosis than occlusive disease, causing death in five patients.",
"     </li>",
"     <li>",
"      Surgical repair was necessary to prevent aneurysm rupture, and postoperative immunosuppressive therapy was necessary to prevent relapse.",
"     </li>",
"     <li>",
"      Glucocorticoids plus other immunosuppression appeared to be more effective than glucocorticoids alone.",
"     </li>",
"     <li>",
"      Anticoagulation was employed successfully in several cases on an empiric basis to prevent postoperative graft thrombosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The outcomes in 25 patients treated for nonpulmonary large-vessel artery disease with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and glucocorticoids pre- and postoperatively were reviewed retrospectively. These included 23 aneurysms and two occlusions [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/105\">",
"     105",
"    </a>",
"    ]. Three patients were treated only medically, and 22 underwent standard surgical procedures, including vascular bypasses, polytetrafluoroethylene (PTFE) bypasses, and ligation. The following were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were three deaths, and one patient was lost to follow-up.",
"     </li>",
"     <li>",
"      Forty percent of PTFE bypasses occluded without disabling consequences.",
"     </li>",
"     <li>",
"      Patients treated with ligation developed mild to moderate claudication.",
"     </li>",
"     <li>",
"      Aneurysms recurred at the anastomotic site in two patients, and new aneurysms developed in three patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vascular complications following arterial bypass surgery are common in patients with Beh&ccedil;et&rsquo;s disease. The most frequent are graft occlusion and aneurysm formation at the anastomotic site. A retrospective study of 10 patients who underwent one or more vascular surgical interventions noted a 24 percent rate of graft occlusion and a 13 percent rate of anastomotic pseudoaneurysm formation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interventional radiologic procedures provide an alternative to surgery for patients with aneurysmal dilation of the aorta or major arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. Percutaneous placement of stent-grafts was successful in six of seven patients with a variety of arterial aneurysms (aortic, subclavian, common carotid, brachiocephalic, and iliac) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/107\">",
"     107",
"    </a>",
"    ]. Arterial occlusion and a recurrent aneurysm beyond the stent-graft occurred in one patient each.",
"   </p>",
"   <p>",
"    A retrospective study reviewed the outcomes of 10 patients with Beh&ccedil;et's and aortic regurgitation treated surgically. In seven patients treated with simple aortic valve replacement, dehiscence occurred in six, leading to 11 reoperations and to one early death. In three patients treated with aortic root replacement, two survived. Of the seven survivors, four eventually required aortic root replacement, and two required heart transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Venous thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous disease in Beh&ccedil;et&rsquo;s disease is believed to result from endothelial inflammation leading to thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/6,110\">",
"     6,110",
"    </a>",
"    ]. The approach to preventing venous thrombotic events in Beh&ccedil;et&rsquo;s disease is control of systemic inflammation rather than the institution of primary anticoagulation. However, if venous thrombotic events occur, they should be treated with anticoagulation using standard approaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A retrospective study of 296 Beh&ccedil;et's patients with venous thrombosis found that 34 percent of patients suffered at least one venous thrombosis relapse. Uses of immunosuppressants and glucocorticoids reduced risk of relapse. Mortality was 6.4 percent at 4.75 years [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complicated venous thrombotic events such as cerebral sinus thrombosis, cerebral vein thrombosis, and pulmonary vein thrombosis can occur in Beh&ccedil;et&rsquo;s disease. The management of these conditions must be handled on a case-by-case basis, through consultation with appropriate subspecialists [",
"    <a class=\"abstract\" href=\"UTD.htm?32/45/33498/abstract/112\">",
"     112",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9482?source=see_link\">",
"     \"Treatment and prognosis of cerebral venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment consists of controlling systemic inflammation associated with Beh&ccedil;et&rsquo;s disease, anticoagulation (generally with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ), and, in some cases, local thrombolysis. Seizures and intracranial hypertension may result from cerebral vein thrombosis, requiring other interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/21/27986?source=see_link\">",
"       \"Patient information: Beh&ccedil;et&rsquo;s disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The literature on the treatment of Beh&ccedil;et&rsquo;s disease consists primarily of case reports and small case series, with few follow-up studies to confirm findings of preliminary reports and with few randomized clinical trials. Treatment is dictated both by the type of organ system involved and by the severity of disease within that organ system. Because many patients have more than one organ system involved, treatment is often guided by the degree of disease severity in the most critical organ. The broad range of disease severity in Beh&ccedil;et&rsquo;s disease can be divided into two categories: items of minor and major severity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of the Beh&ccedil;et&rsquo;s literature'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Minor disease manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor disease manifestations are those that interfere substantially with patients' quality of life but do not threaten vital organ function. Examples of minor disease manifestations are arthritis and mucocutaneous disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For arthritis, oral aphthae, genital ulcers, and other skin manifestations that are relatively mild, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      as the initial therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The typical daily dose ranges from 1 to 2 mg.",
"     </li>",
"     <li>",
"      We suggest considering glucocorticoids or other immunosuppressive agents early in the course of erythema nodosum and pyoderma gangrenosum (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Other skin lesions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For minor disease manifestations not responsive to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      , systemic glucocorticoids may be required. The dosing of glucocorticoids depends on the specific clinical indication. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment by organ system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of other immunosuppressive and immunomodulatory agents have also been evaluated for the treatment of minor disease manifestations, some in randomized clinical trials. Use of these medications may be appropriate in the setting of resistant disease or glucocorticoid-related morbidity. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Available pharmacologic agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Major disease manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major disease manifestations are those that may lead to the dysfunction of major organs and even to death. These include certain ocular and neurological manifestations, as well as complications of large-vessel arteritis and venous thrombotic disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anterior uveitis must be treated with topical corticosteroids with a mydriatic (eye dilating) agent to prevent synechiae formation between the iris and lens.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"       Scopolamine",
"      </a>",
"      (0.25 percent) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/34/24100?source=see_link\">",
"       cyclopentolate",
"      </a>",
"      (1 percent) is usually used for this purpose.",
"     </li>",
"     <li>",
"      Posterior uveitis poses a major threat to vision. We recommend initiating treatment as soon as possible with both high-dose glucocorticoids and a second immunosuppressive agent (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ):",
"     </li>",
"     <li>",
"      Glucocorticoids - We typically employ an initial",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, not to exceed 80",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Posterior uveitis and other major disease manifestations'",
"      </a>",
"      above.) Pulse therapy with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      for three days) may be used empirically for organ- or life-threatening disease.",
"     </li>",
"     <li>",
"      Second immunosuppressive agent -",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      are the current options for the choice of a second immunosuppressive agent in patients requiring a steroid-sparing agent or additional therapeutic benefit to that provided by glucocorticoids alone. We suggest azathioprine, azathioprine plus infliximab, or azathioprine plus cyclosporine as the agents of choice for such patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Other options that may be utilized include interferon alfa and other anti-TNF agents.",
"     </li>",
"     <li>",
"      Among the neurological manifestations, encephalitis, medium-vessel vasculitis, and focal parenchymal lesions of significant size should be treated in the same manner as posterior uveitis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Neurologic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Arterial involvement in Beh&ccedil;et&rsquo;s disease sometimes leads to dilatations and aneurysms of medium- and large-sized arteries. These complications may require combined medical and surgical or interventional radiology treatments. Unless intervention is required urgently, it is prudent to postpone invasive approaches to these vascular complications until the inflammatory component of Beh&ccedil;et&rsquo;s disease has been controlled with medical therapy. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Large artery disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Venous thrombotic events in Beh&ccedil;et&rsquo;s disease are believed to be related to vascular inflammation rather than inherent problems with coagulation. Thus, anti-inflammatory approaches to therapy are appropriate simultaneous to anti-coagulation. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Venous thrombosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/1\">",
"      Saenz A, Ausejo M, Shea B, et al. Pharmacotherapy for Behcet's syndrome. Cochrane Database Syst Rev 2000; :CD001084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/2\">",
"      Yurdakul S, Mat C, T&uuml;z&uuml;n Y, et al. A double-blind trial of colchicine in Beh&ccedil;et's syndrome. Arthritis Rheum 2001; 44:2686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/3\">",
"      Hatemi G, Silman A, Bang D, et al. Management of Beh&ccedil;et disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Beh&ccedil;et disease. Ann Rheum Dis 2009; 68:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/4\">",
"      Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Beh&ccedil;et disease. Ann Rheum Dis 2008; 67:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/5\">",
"      Pipitone N, Olivieri I, Cantini F, et al. New approaches in the treatment of Adamantiades-Beh&ccedil;et's disease. Curr Opin Rheumatol 2006; 18:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/6\">",
"      Barnes CG. Treatment of Behcet's syndrome. Rheumatology (Oxford) 2006; 45:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/7\">",
"      Mat C, Yurdakul S, Uysal S, et al. A double-blind trial of depot corticosteroids in Beh&ccedil;et's syndrome. Rheumatology (Oxford) 2006; 45:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/8\">",
"      Kaklamani VG, Kaklamanis PG. Treatment of Beh&ccedil;et's disease--an update. Semin Arthritis Rheum 2001; 30:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/9\">",
"      Aktulga E, Alta&ccedil; M, M&uuml;ft&uuml;oglu A, et al. A double blind study of colchicine in Beh&ccedil;et's disease. Haematologica 1980; 65:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/10\">",
"      Kazokoglu H, Saat&ccedil;i O, Cuhadaroglu H, Eldem B. Long-term effects of cyclophosphamide and colchicine treatment in Beh&ccedil;et's disease. Ann Ophthalmol 1991; 23:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/11\">",
"      Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Beh&ccedil;et's disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol 2009; 19:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/12\">",
"      Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Beh&ccedil;et's syndrome. N Engl J Med 1990; 322:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/13\">",
"      Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum 1997; 40:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/14\">",
"      Saadoun D, Wechsler B, Terrada C, et al. Azathioprine in severe uveitis of Beh&ccedil;et's disease. Arthritis Care Res (Hoboken) 2010; 62:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/15\">",
"      Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Beh&ccedil;et's syndrome: a single masked trial. Br J Ophthalmol 1992; 76:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/16\">",
"      Hamza M, Meddeb S, Mili I, Ouertani A. [Bolus of cyclophosphamide and methylprednisolone in uveitis in Beh&ccedil;et's disease. Preliminary results with the use of new criteria of evaluation]. Ann Med Interne (Paris) 1992; 143:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/17\">",
"      Du LT, Fain O, Wechsler B, et al. [Value of \"bolus\" cyclophosphamide injections in Beh&ccedil;et's disease. Experience of 17 cases]. Presse Med 1990; 19:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/18\">",
"      Atmaca LS, Batiolu F. The efficacy of cyclosporin-a in the treatment of Beh&ccedil;et's disease. Ophthalmic Surg 1994; 25:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/19\">",
"      Sajjadi H, Soheilian M, Ahmadieh H, et al. Low dose cyclosporin-A therapy in Beh&ccedil;et's disease. J Ocul Pharmacol 1994; 10:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/20\">",
"      Whitcup SM, Salvo EC Jr, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Beh&ccedil;et's disease. Am J Ophthalmol 1994; 118:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/21\">",
"      BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Beh&ccedil;et's syndrome. Transplant Proc 1988; 20:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/22\">",
"      K&ouml;tter I, G&uuml;naydin I, Batra M, et al. CNS involvement occurs more frequently in patients with Beh&ccedil;et's disease under cyclosporin A (CSA) than under other medications--results of a retrospective analysis of 117 cases. Clin Rheumatol 2006; 25:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/23\">",
"      Sakane T, Takeno M. Novel approaches to Beh&ccedil;et's disease. Expert Opin Investig Drugs 2000; 9:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/24\">",
"      Marshall SE. Beh&ccedil;et's disease. Best Pract Res Clin Rheumatol 2004; 18:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/25\">",
"      Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. Rheumatology (Oxford) 2007; 46:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/26\">",
"      Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Beh&ccedil;et's disease. Lancet 2001; 358:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/27\">",
"      Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Beh&ccedil;et's disease: a case report. Gastroenterology 2001; 120:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/28\">",
"      Rozenbaum M, Rosner I, Portnoy E. Remission of Beh&ccedil;et's syndrome with TNFalpha blocking treatment. Ann Rheum Dis 2002; 61:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/29\">",
"      Wechsler B, Sabl&eacute;-Fourtassou R, Bodaghi B, et al. Infliximab in refractory uveitis due to Beh&ccedil;et's disease. Clin Exp Rheumatol 2004; 22:S14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/30\">",
"      Sarwar H, McGrath H Jr, Espinoza LR. Successful treatment of long-standing neuro-Beh&ccedil;et's disease with infliximab. J Rheumatol 2005; 32:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/31\">",
"      Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, et al. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye (Lond) 2005; 19:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/32\">",
"      Lanthier N, Parc C, Scavennec R, et al. Infliximab in the treatment of posterior uveitis in Beh&ccedil;et's disease. Long term follow up in four patients. Presse Med 2005; 34:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/33\">",
"      Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh&ccedil;et's disease with refractory uveoretinitis. J Rheumatol 2004; 31:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/34\">",
"      Rosenbaum JT. Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Beh&ccedil;et's disease. J Rheumatol 2004; 31:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/35\">",
"      Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Beh&ccedil;et disease. Ann Intern Med 2004; 140:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/36\">",
"      Yamada Y, Sugita S, Tanaka H, et al. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Beh&ccedil;et disease. Br J Ophthalmol 2010; 94:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/37\">",
"      Giardina A, Ferrante A, Ciccia F, et al. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Beh&ccedil;et's disease refractory to standard immunosuppressive drugs. Rheumatol Int 2011; 31:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/38\">",
"      Iwata S, Saito K, Yamaoka K, et al. Efficacy of combination therapy of anti-TNF-&alpha; antibody infliximab and methotrexate in refractory entero-Beh&ccedil;et's disease. Mod Rheumatol 2011; 21:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/39\">",
"      Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Beh&ccedil;et disease. Am J Ophthalmol 2008; 146:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/40\">",
"      Pipitone N, Olivieri I, Padula A, et al. Infliximab for the treatment of Neuro-Beh&ccedil;et's disease: a case series and review of the literature. Arthritis Rheum 2008; 59:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/41\">",
"      Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005; 89:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/42\">",
"      Capella MJ, Foster CS. Long-term efficacy and safety of infliximab in the treatment of Beh&ccedil;et's disease. Ocul Immunol Inflamm 2012; 20:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/43\">",
"      Takeuchi M, Asukata Y, Kawagoe T, et al. Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Beh&ccedil;et's disease. Ocul Immunol Inflamm 2012; 20:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/44\">",
"      Cantini F, Niccoli L, Nannini C, et al. Efficacy of infliximab in refractory Beh&ccedil;et's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. Biologics 2012; 6:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/45\">",
"      Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Beh&ccedil;et's disease: a double blind, placebo controlled study. J Rheumatol 2005; 32:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/46\">",
"      Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Beh&ccedil;et disease. Ocul Immunol Inflamm 2010; 18:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/47\">",
"      Olivieri I, Leccese P, D'Angelo S, et al. Efficacy of adalimumab in patients with Beh&ccedil;et's disease unsuccessfully treated with infliximab. Clin Exp Rheumatol 2011; 29:S54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/48\">",
"      Calvo Catal&aacute; J, Campos Fern&aacute;ndez C, Rueda Cid A, et al. [Efficacy of adalimumab in Beh&ccedil;et's disease. Description of 6 cases]. Reumatol Clin 2011; 7:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/49\">",
"      D&iacute;az-Llopis M, Salom D, Garcia-de-Vicu&ntilde;a C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 2012; 119:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/50\">",
"      Pivetti-Pezzi P, Accorinti M, Pirraglia MP, et al. Interferon alpha for ocular Beh&ccedil;et's disease. Acta Ophthalmol Scand 1997; 75:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/51\">",
"      Mochizuki M. Immunotherapy for Beh&ccedil;et's disease. Int Rev Immunol 1997; 14:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/52\">",
"      Nichols JC, Ince A, Akduman L, Mann ES. Interferon-alpha 2a treatment of neuro-Behcet disease. J Neuroophthalmol 2001; 21:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/53\">",
"      Zouboulis CC, Orfanos CE. Treatment of Adamantiades-Beh&ccedil;et disease with systemic interferon alfa. Arch Dermatol 1998; 134:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/54\">",
"      Hamuryudan V, Moral F, Yurdakul S, et al. Systemic interferon alpha 2b treatment in Beh&ccedil;et's syndrome. J Rheumatol 1994; 21:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/55\">",
"      Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Beh&ccedil;et disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002; 138:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/56\">",
"      Deuter CM, K&ouml;tter I, G&uuml;naydin I, et al. [Ocular involvement in Beh&ccedil;et's disease: first 5-year-results for visual development after treatment with interferon alfa-2a]. Ophthalmologe 2004; 101:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/57\">",
"      K&ouml;tter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Beh&ccedil;et's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003; 87:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/58\">",
"      Alpsoy E, Yilmaz E, Baaran E. Interferon therapy for Beh&ccedil;et's disease. J Am Acad Dermatol 1994; 31:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/59\">",
"      O'Duffy JD, Calamia K, Cohen S, et al. Interferon-alpha treatment of Beh&ccedil;et's disease. J Rheumatol 1998; 25:1938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/60\">",
"      Kuemmerle-Deschner JB, Tzaribachev N, Deuter C, et al. Interferon-alpha--a new therapeutic option in refractory juvenile Beh&ccedil;et's disease with CNS involvement. Rheumatology (Oxford) 2008; 47:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/61\">",
"      Yal&ccedil;inda FN, Uzun A. Results of interferon alpha-2a therapy in patients with Behcet's disease. J Ocul Pharmacol Ther 2012; 28:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/62\">",
"      K&ouml;tter I, G&uuml;naydin I, Zierhut M, St&uuml;biger N. The use of interferon alpha in Beh&ccedil;et disease: review of the literature. Semin Arthritis Rheum 2004; 33:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/63\">",
"      K&ouml;tter I, Vonthein R, Zierhut M, et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Beh&ccedil;et disease: results of an open 4-center trial. Semin Arthritis Rheum 2004; 33:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/64\">",
"      Deuter CM, Zierhut M, M&ouml;hle A, et al. Long-term remission after cessation of interferon-&alpha; treatment in patients with severe uveitis due to Beh&ccedil;et's disease. Arthritis Rheum 2010; 62:2796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/65\">",
"      Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Beh&ccedil;et uveitis. Arch Ophthalmol 2011; 129:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/66\">",
"      Sobaci G, Erdem U, Durukan AH, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Beh&ccedil;et's uveitis refractory to conventional treatments. Ophthalmology 2010; 117:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/67\">",
"      Adler YD, Mansmann U, Zouboulis CC. Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Beh&ccedil;et's disease. Dermatology 2001; 203:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/68\">",
"      Shugaiv E, T&uuml;z&uuml;n E, Mutlu M, et al. Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Beh&ccedil;et's disease with parenchymal involvement: presentation of four cases. Clin Exp Rheumatol 2011; 29:S64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/69\">",
"      Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Beh&ccedil;et syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/70\">",
"      Ehrlich GE. Beh&ccedil;et disease and the emergence of thalidomide. Ann Intern Med 1998; 128:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/71\">",
"      Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). Int J Rheum Dis 2010; 13:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/72\">",
"      Seider N, Beiran I, Scharf J, Miller B. Intravenous immunoglobulin therapy for resistant ocular Beh&ccedil;et's disease. Br J Ophthalmol 2001; 85:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/73\">",
"      Russell AI, Lawson WA, Haskard DO. Potential new therapeutic options in Beh&ccedil;et's syndrome. BioDrugs 2001; 15:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/74\">",
"      Boyvat A, Siman-Solak C, G&uuml;rler A. Long-term effects of interferon alpha 2A treatment in Beh&ccedil;et's disease. Dermatology 2000; 201:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/75\">",
"      Lockwood CM, Hale G, Waldman H, Jayne DR. Remission induction in Beh&ccedil;et's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford) 2003; 42:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/76\">",
"      Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Beh&ccedil;et's disease: a double-blind, placebo-controlled, cross-over study. J Dermatol 2002; 29:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/77\">",
"      Matsuda T, Ohno S, Hirohata S, et al. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Beh&ccedil;et's disease: a randomised, double-blind, placebo-controlled study. Drugs R D 2003; 4:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/78\">",
"      Hensel M, Breitbart A, Ho AD. Autologous hematopoietic stem-cell transplantation for Beh&ccedil;et's disease with pulmonary involvement. N Engl J Med 2001; 344:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/79\">",
"      Rossi G, Moretta A, Locatelli F. Autologous hematopoietic stem cell transplantation for severe/refractory intestinal Behcet disease. Blood 2004; 103:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/80\">",
"      Tomonari A, Tojo A, Takahashi T, et al. Resolution of Beh&ccedil;et's disease after HLA-mismatched unrelated cord blood transplantation for myelodysplastic syndrome. Ann Hematol 2004; 83:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/81\">",
"      Stanford M, Whittall T, Bergmeier LA, et al. Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease. Clin Exp Immunol 2004; 137:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/82\">",
"      Alpsoy E, Er H, Durusoy C, Yilmaz E. The use of sucralfate suspension in the treatment of oral and genital ulceration of Beh&ccedil;et disease: a randomized, placebo-controlled, double-blind study. Arch Dermatol 1999; 135:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/83\">",
"      Tellier Z. Intravenous immunoglobulin in eye involvement. Clin Rev Allergy Immunol 2005; 29:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/84\">",
"      Namba K, Sonoda KH, Kitamei H, et al. Granulocytapheresis in patients with refractory ocular Behcet's disease. J Clin Apher 2006; 21:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/85\">",
"      Alpsoy E. Beh&ccedil;et's disease: treatment of mucocutaneous lesions. Clin Exp Rheumatol 2005; 23:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/86\">",
"      Chams-Davatchi C, Barikbin B, Shahram F, et al. Pimecrolimus versus placebo in genital aphthous ulcers of Behcet's disease: a randomized double-blind controlled trial. Int J Rheum Dis 2010; 13:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/87\">",
"      Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Beh&ccedil;et's disease. Lancet 1989; 1:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/88\">",
"      Gardner-Medwin JM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Beh&ccedil;et's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994; 53:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/89\">",
"      Kim B, LeBoit PE. Histopathologic features of erythema nodosum--like lesions in Beh&ccedil;et disease: a comparison with erythema nodosum focusing on the role of vasculitis. Am J Dermatopathol 2000; 22:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/90\">",
"      Sakane T, Takeno M, Suzuki N, Inaba G. Beh&ccedil;et's disease. N Engl J Med 1999; 341:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/91\">",
"      Reed JB, Morse LS, Schwab IR. High-dose intravenous pulse methylprednisolone hemisuccinate in acute Beh&ccedil;et retinitis. Am J Ophthalmol 1998; 125:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/92\">",
"      Tuncer S, Yilmaz S, Urgancioglu M, Tugal-Tutkun I. Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Beh&ccedil;et disease. J Ocul Pharmacol Ther 2007; 23:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/93\">",
"      Hamuryudan V, Ozyazgan Y, Fresko Y, et al. Interferon alfa combined with azathioprine for the uveitis of Beh&ccedil;et's disease: an open study. Isr Med Assoc J 2002; 4:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/94\">",
"      Deuter CM, K&ouml;tter I, G&uuml;naydin I, et al. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol 2009; 93:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/95\">",
"      Ward EM, Woodward TA, Mazlumzadeh M, Calamia KT. Gastrointestinal disease in Beh&ccedil;et's disease. Adv Exp Med Biol 2003; 528:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/96\">",
"      Travis SP, Czajkowski M, McGovern DP, et al. Treatment of intestinal Beh&ccedil;et's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 2001; 49:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/97\">",
"      Kram MT, May LD, Goodman S, Molinas S. Beh&ccedil;et's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 2003; 46:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/98\">",
"      Altiparmak MR, Tanverdi M, Pamuk ON, et al. Glomerulonephritis in Beh&ccedil;et's disease: report of seven cases and review of the literature. Clin Rheumatol 2002; 21:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/99\">",
"      Akpolat T, Akkoyunlu M, Akpolat I, et al. Renal Beh&ccedil;et's disease: a cumulative analysis. Semin Arthritis Rheum 2002; 31:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/100\">",
"      Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Beh&ccedil;et disease. Curr Opin Rheumatol 2005; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/101\">",
"      Hamuryudan V, Er T, Seyahi E, et al. Pulmonary artery aneurysms in Beh&ccedil;et syndrome. Am J Med 2004; 117:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/102\">",
"      Adler S, Baumgartner I, Villiger PM. Beh&ccedil;et's disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis. Arthritis Care Res (Hoboken) 2012; 64:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/103\">",
"      Iscan ZH, Vural KM, Bayazit M. Compelling nature of arterial manifestations in Behcet disease. J Vasc Surg 2005; 41:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/104\">",
"      L&ecirc; Thi Huong D, Wechsler B, Papo T, et al. Arterial lesions in Beh&ccedil;et's disease. A study in 25 patients. J Rheumatol 1995; 22:2103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/105\">",
"      Tuzun H, Seyahi E, Arslan C, et al. Management and prognosis of nonpulmonary large arterial disease in patients with Beh&ccedil;et disease. J Vasc Surg 2012; 55:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/106\">",
"      Hosaka A, Miyata T, Shigematsu H, et al. Long-term outcome after surgical treatment of arterial lesions in Beh&ccedil;et disease. J Vasc Surg 2005; 42:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/107\">",
"      Park JH, Chung JW, Joh JH, et al. Aortic and arterial aneurysms in beh&ccedil;et disease: management with stent-grafts--initial experience. Radiology 2001; 220:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/108\">",
"      Nitecki SS, Ofer A, Karram T, et al. Abdominal aortic aneurysm in Beh&ccedil;et's disease: new treatment options for an old and challenging problem. Isr Med Assoc J 2004; 6:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/109\">",
"      Ma WG, Zheng J, Zhu JM, et al. Aortic regurgitation caused by Beh&ccedil;et's disease: surgical experience during an 11-year period. J Card Surg 2012; 27:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/110\">",
"      Mader R, Ziv M, Adawi M, et al. Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Beh&ccedil;et's disease. J Rheumatol 1999; 26:2404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/111\">",
"      Desbois AC, Wechsler B, Resche-Rigon M, et al. Immunosuppressants reduce venous thrombosis relapse in Beh&ccedil;et's disease. Arthritis Rheum 2012; 64:2753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/45/33498/abstract/112\">",
"      Saadoun D, Wechsler B, Resche-Rigon M, et al. Cerebral venous thrombosis in Beh&ccedil;et's disease. Arthritis Rheum 2009; 61:518.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8239 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4FB60DB4AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_45_33498=[""].join("\n");
var outline_f32_45_33498=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF THE BEH&Ccedil;ET&rsquo;S LITERATURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      AVAILABLE PHARMACOLOGIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1464079\">",
"      Colchicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Anti-TNF-alpha therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Infliximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Etanercept",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1464191\">",
"      - Adalimumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Interferon alfa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Thalidomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1464279\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT BY ORGAN SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Mucocutaneous manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Oral aphthae and genital ulcers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Other skin lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Ocular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Anterior uveitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Posterior uveitis and other major disease manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Neurologic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Large artery disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Minor disease manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Major disease manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=related_link\">",
"      Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13130?source=related_link\">",
"      Erythema nodosum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=related_link\">",
"      Infliximab in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28874?source=related_link\">",
"      Pathogenesis of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/21/27986?source=related_link\">",
"      Patient information: Beh&ccedil;et&rsquo;s disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/61/10202?source=related_link\">",
"      Pyoderma gangrenosum: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=related_link\">",
"      Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/16/9482?source=related_link\">",
"      Treatment and prognosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23383?source=related_link\">",
"      Treatment of secondary (AA) amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/10/10407?source=related_link\">",
"      Uveitis: Treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_45_33499="Use of SCOOP system II";
var content_f32_45_33499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patient management tips for the SCOOP transtracheal oxygen system - II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Phase",
"       </td>",
"       <td class=\"subtitle1\">",
"        Goal",
"       </td>",
"       <td class=\"subtitle1\">",
"        Management strategy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        II",
"       </td>",
"       <td>",
"        Prevent infection",
"       </td>",
"       <td>",
"        Instruct the patient in the importance of taking antibiotics for the time prescribed. This prevents infection and may reduce the risk of chondritis. Teach the patient to clean the site daily with 1/2 strength hydrogen peroxide; evaluate for warmth, redness, swelling, or drainage; and report these symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minimize cough",
"       </td>",
"       <td>",
"        Encourage the patient to use guaifenesin for mild cough. Oral narcotics (eg, dextromethorphan, codeine) may be prescribed for moderate cough. Severe, uncontrolled cough can be relieved by instructing the patient to inject 0.5 to 1 mL 1 percent lidocaine into the stent every 4 to 6 hours&nbsp;as needed&nbsp;for 24 hours.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Anticipate air leaks",
"       </td>",
"       <td>",
"        Stent patients: Alert the patient to expect some air loss and secretions through the stent for 1 to 2 days until it becomes blocked by secretions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fast Tract patients will have some air loss and secretions from the stoma while it is healing and may have difficulty speaking for the first few days. The patient can apply gentle pressure to the SCOOP flange to make speaking easier.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Hoffman LA, Wesmiller SW.Transtracheal oxygen. In: Portable Oxygen Therapy: Including Oxygen Conserving Methodology, Tiep BL (Ed), Mount Kisco, NY, 1991.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_45_33499=[""].join("\n");
var outline_f32_45_33499=null;
var title_f32_45_33500="Differential diagnosis of GBS";
var content_f32_45_33500=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F80040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F80040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of Guillain-Barr&eacute; syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Differential diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Cerebral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bilateral strokes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Psychogenic symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Cerebellar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute cerebellar ataxia syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Posterior fossa structural lesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Spinal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Compressive myelopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Transverse myelitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anterior spinal artery syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Poliomyelitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other infectious causes of acute myelitis (eg, West Nile virus, coxsackieviruses, echoviruses)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Peripheral nervous system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Toxic neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Toxins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Critical care neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diphtheria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tick paralysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Porphyria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lyme disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Neuromuscular junction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Botulism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myasthenia gravis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neuromuscular blocking agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Muscle disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute viral myositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute inflammatory myopathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metabolic myopathies (eg, hypokalemic, hyperkalemic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Periodic paralysis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Evans OB. Guillain-Barr&eacute; syndrome in children. Pediatr Rev 1986; 8:69.",
"      </li>",
"      <li>",
"       Jones HR. Childhood Guillain-Barr&eacute; syndrome: clinical presentation, diagnosis, and therapy. J Child Neurol 1996; 11:4.",
"      </li>",
"      <li>",
"       Yuki N, Hartung HP. Guillain-Barr&eacute; syndrome. N Engl J Med 2012; 366:2294.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_45_33500=[""].join("\n");
var outline_f32_45_33500=null;
var title_f32_45_33501="Dobutamine echo surgical risk";
var content_f32_45_33501=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77763&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Role of dobutamine echocardiography in assessing risk for noncardiac vascular surgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 317px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hazard ratios for late cardiac events (cardiac death, myocardial infarction, or need for revascularization) after major vascular surgery correlate with a previous myocardial infarction (MI) and the number of ischemic segments as determined from a dobutamine stress echocardiogram. Patients with a previous MI and three or more ischemic segments were at highest risk (top row). Error bars represent 95 percent confidence intervals.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Poldermans D, Arnese M, Fioretti PM, et al. Circulation 1997; 95:53.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_45_33501=[""].join("\n");
var outline_f32_45_33501=null;
var title_f32_45_33502="Pancreatic tumor pancreatoscopy";
var content_f32_45_33502=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatoscopy showing a pancreatic tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Identification of the papillary projections by pancreatoscopy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Levy, MD, Enrique Vazquez-Sequeiros, MD, and Maurits J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_45_33502=[""].join("\n");
var outline_f32_45_33502=null;
var title_f32_45_33503="Hysteroscopy tamoxifen pt";
var content_f32_45_33503=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hysteroscopic view of a patient on tamoxifen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This hysteroscopic view of the uterine cavity of a patient on tamoxifen shows atrophic surface epithelium and microcystic fluid blebs under the surface epithelium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_45_33503=[""].join("\n");
var outline_f32_45_33503=null;
